1,436 Matching Annotations
  1. Last 7 days
    1. mutations

      Case#: UK 130, Malmo 19, UK 134, Malmo 6, UK 129, Malmo 40, Malmo 20 (assumed male, from UK and Malmö, Sweden)

      DiseaseAssertion: UK 130: Moderate Hemophilia B Malmo 19: Moderate Hemophilia B UK 134: Severe Hemophilia B Malmo 6: Severe Hemophilia B UK 129: Moderate Hemophilia B Malmo 40: Moderate Hemophilia B Malmo 20: Moderate Hemophilia B

      FamilyInfo: None

      ParentalTesting: N/A

      CasePresentingHPOs: reduced factor IX activity

      CaseHPOsFreeText: UK 130 FIX:C: 1.6 Malmo 19 FIX:C: 2.3 ; FIX:AG: 36 UK 134 FIX:C: <1 Malmo 6 FIX:C: <1 ; FIX:AG: 26-35 UK 129 FIX:C: 4 Malmo 40 FIX:C: 1 ; FIX:AG: 30 Malmo 20 FIX:C: 2 ; FIX:AG: 27

      CaseNotHPOs: N/A

      CasePreviousTesting: N/A

      Gene: F9

      Variant: NM_000133.4:c.127C>T (p.Arg43Trp)

      ClinVar: 811505

      CAID: CA414435537

      gnomAD: Absent/Not Reported

    1. c.6506G>A

      Case#: 31

      DiseaseAssertion: Hemophilia A

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: NA

      CaseHPOFreeText: FVIII:C 17/25%, Mild Phenotype, inhibitors present

      CasePreviousTesting: Screened for IVS-22 and IVS-1, sample was blinded for NGS and the sequencing component was validated by comparing results with Sanger Sequencing

      Gene: F8

      Variant: NM_000132.3(F8):c.6506G>A (p.Arg2169His)

      ClinVar: 10315 https://www.ncbi.nlm.nih.gov/clinvar/variation/10315/

      CAID: CA255208

      gnomAD: Not reported

    2. c.5954G>A

      Case#: 24

      DiseaseAssertion: Hemophilia A

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: NA

      CaseHPOFreeText: FVIII:C 23/18%, Mild Phenotype, No inhibitors present

      CasePreviousTesting: Screened for IVS-22 and IVS-1, sample was blinded for NGS and the sequencing component was validated by comparing results with Sanger Sequencing

      Gene: F8

      Variant: NM_000132.3(F8):c.5954G>A (p.Arg1985Gln)

      ClinVar: 618098 https://www.ncbi.nlm.nih.gov/clinvar/variation/618098/

      CAID: CA414905715

      gnomAD: MAF for Arg1985Gln in the European (non-Finnish) population 0.00001224<br> https://gnomad.broadinstitute.org/variant/X-154132225-C-T?dataset=gnomad_r2_1

    3. c.6977G>A

      Case#: 37

      DiseaseAssertion: Hemophilia A

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: NA

      CaseHPOFreeText: FVIII:C 36%, Mild Phenotype, No inhibitors present

      CasePreviousTesting: Screened for IVS-22 and IVS-1, sample was blinded for NGS and the sequencing component was validated by comparing results with Sanger Sequencing

      Gene: F8

      Variant: NM_000132.3(F8):c.6977G>A (p.Arg2326Gln)

      ClinVar: 10126 https://www.ncbi.nlm.nih.gov/clinvar/variation/10126/

      CAID: CA255027

      gnomAD: Not reported

    4. c.197A>T

      Case#: 1

      DiseaseAssertion: Hemophilia A

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: NA

      CaseHPOFreeText: FVIII:C 21% (Mild Phenotype), No inhibitors present

      CasePreviousTesting: Screened for IVS-22 and IVS-1, sample was blinded for NGS and the sequencing component was validated by comparing results with Sanger Sequencing

      Gene: F8

      Variant: NM_000132.3:c.197A>T (p.Lys66Ile)

      ClinVar: NA

      CAID: CA414920295

      gnomAD: Not reported

    1. 99

      Case#: 99, male, 9 years old, Chinese

      DiseaseAssertion: Hemophilia A, severe

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C < 1%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: F8 gene variants were identified using next-generation sequencing (NGS), inverse shifting PCR and MLPA

      Gene: F8

      Variant: NM_000132.3:c.6544C>T

      LegacyVariant:

      ClinVar: 10321

      CAID: CA255214

      gnomAD:

    2. 92

      Case#: 92, male, 61 years old, Chinese

      DiseaseAssertion: Hemophilia A, moderate

      FamilyInfo: Noted Family History

      ParentalTesting: Maternity confirmed

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C = 4.2%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: F8 gene variants were identified using next-generation sequencing (NGS), inverse shifting PCR and MLPA

      Gene: F8

      Variant: NM_000132.3:c.6440G>T

      LegacyVariant:

      ClinVar: No

      CAID: CA414908004

      gnomAD:

    3. 106

      Case#: 106, male, 12 years old, Chinese

      DiseaseAssertion: Hemophilia A, severe

      FamilyInfo: Noted Family History

      ParentalTesting: Maternity confirmed

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C < 1%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: F8 gene variants were identified using next-generation sequencing (NGS), inverse shifting PCR and MLPA

      Gene: F8

      Variant: NM_000132.3:c.6683G>A

      LegacyVariant:

      ClinVar: 10098

      CAID: CA255016

      gnomAD:

    4. 54

      Case#: 54, male, 9 years old, Chinese

      DiseaseAssertion: Hemophilia A, mild

      FamilyInfo: NA

      ParentalTesting: Maternity confirmed

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C = 17%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: F8 gene variants were identified using next-generation sequencing (NGS), inverse shifting PCR and MLPA

      Gene: F8

      Variant: NM_000132.3:c.1834C>T

      LegacyVariant:

      ClinVar: 10236

      CAID: CA255129

      gnomAD:

    5. 83

      Case#: 83, male, 17 years old, Chinese

      DiseaseAssertion: Hemophilia A, severe

      FamilyInfo: NA

      ParentalTesting: Maternity confirmed

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C < 1%, Inhibitor present

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: F8 gene variants were identified using next-generation sequencing (NGS), inverse shifting PCR and MLPA

      Gene: F8

      Variant: NM_000132.3:c.5816C>A

      LegacyVariant:

      ClinVar: No

      CAID: CA414906727

      gnomAD:

    6. 68

      Case#: 68, male, 10 years old, Chinese

      DiseaseAssertion: Hemophilia A, severe

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C < 1%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: F8 gene variants were identified using next-generation sequencing (NGS), inverse shifting PCR and MLPA

      Gene: F8

      Variant: NM_000132.3:c.3780C>G

      LegacyVariant:

      ClinVar: 40999

      CAID: CA343865

      gnomAD:

    7. 96

      Case#: 96, male, 55 years old, Chinese

      DiseaseAssertion: Hemophilia A, moderate

      FamilyInfo: Noted Family History

      ParentalTesting: Maternity confirmed

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C = 1.2%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: F8 gene variants were identified using next-generation sequencing (NGS), inverse shifting PCR and MLPA

      Gene: F8

      Variant: NM_000132.3:c.6515C>T

      LegacyVariant:

      ClinVar: No

      CAID: CA414907354

      gnomAD:

    8. 48

      Case#: 48, male, 37 years old, Chinese

      DiseaseAssertion: Hemophilia A, moderate

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C = 1.2%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: F8 gene variants were identified using next-generation sequencing (NGS), inverse shifting PCR and MLPA

      Gene: F8

      Variant: NM_000132.3:c.1331A>C

      LegacyVariant:

      ClinVar: No

      CAID: CA414914983

      gnomAD:

    1. Val37 mutation.

      Case#: Patient R (male, 83 y/o)

      DiseaseAssertion: Severe Hemophilia B

      FamilyInfo: N/A

      ParentalTesting: N/A

      CasePresentingHPOs: HP:0011858, HP:0012233

      CaseHPOsFreeText: reduced factor IX activity (FIX:C: 2.4%), extensive subcutaneous bleeding

      CaseNotHPOs: None

      CasePreviousTesting: N/A

      Gene: F9

      Variant: NM_000133.4:c.110C>T (p.Ala37Val)

      ClinVar: Absent

      CAID: CA414435437

      gnomAD: Allele Frequency (European-non Finnish): 0.00002186

    2. Thr37

      Case#: Pezeshkpoor_Patient_N (male, 68 y/o, from Switzerland)

      DiseaseAssertion: Hemophilia B

      FamilyInfo: The daughter of the patient has the mutation, while the brother of the patient does not.

      ParentalTesting: N/A

      CasePresentingHPOs: HP:0011858

      CaseHPOsFreeText: mechanical aoritc valve replacement, low FIX:C levels

      CasePreviousTesting: N/A

      Gene: F9

      Variant: NM_000133.4:c.109G>A (p.Ala37Thr)

      ClinVar: 804089

      CAID: CA10529736

      gnomAD: Allele Frequency in population where variant was found in the highest (South Asian population): 0.0001128

    1. 8.

      Case#: 8

      DiseaseAssertion: Hemophilia B, severe

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0011858

      CaseHPOFreeText: FIX:C < 1%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: All relevant sequences of F9 were PCR amplified and analyzed by DNA sequencing

      Gene: F9

      Variant: NM_000133.3:c.422G>A

      LegacyVariant:

      ClinVar: No

      CAID: CA414438897

      gnomAD:

    2. 21.

      Case#: 21

      DiseaseAssertion: Hemophilia B, moderate

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0011858

      CaseHPOFreeText: FIX:C = 2%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: All relevant sequences of F9 were PCR amplified and analyzed by DNA sequencing

      Gene: F9

      Variant: NM_000133.3:c.1136G>A

      LegacyVariant:

      ClinVar: No

      CAID: CA255394

      gnomAD:

    3. 15.

      Case#: 15

      DiseaseAssertion: Hemophilia B, moderate

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0011858

      CaseHPOFreeText: FIX:C = 3.5%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: All relevant sequences of F9 were PCR amplified and analyzed by DNA sequencing

      Gene: F9

      Variant: NM_000133.3:c.881G>A

      LegacyVariant:

      ClinVar: No

      CAID: CA255368

      gnomAD:

    1. Case: P57, Chinese, male, 28yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type AB blood, bleeding score = 5; VWF:Ag (%) = 33.4, VWF:RCo (%) = 3.2, FVIII:C (%) = 49.2, VWF:CB (%) = 4.8, VWFpp (%) = 67.3, VWF:RCo/VWF:Ag = 0.1, VWF:CB/VWF:Ag = 0.1, VWFpp/VWF:Ag = 2.0, FVIII:C/VWF:Ag = 1.5, RIPA (0.5 mg/ml, %) = 18.2, PLT(×109/l) = 146

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.2089G>C (p.Glu697Gln)

      HGVS: NM_000552.5:c.2089G>C (p.Glu697Gln)

      ClinVarID: NA

      CAID: CA383494704; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383494704

      gnomAD: absent

      Variant 2: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

      Variant 3: c.8113G>A (p.Gly2705Arg)

      HGVS: NM_000552.4(VWF):c.8113G>A (p.Gly2705Arg)

      ClinVarID: 256702; https://www.ncbi.nlm.nih.gov/clinvar/variation/256702/

      CAID: NA

      gnomAD: MAF = 0.1254 (3839/30614 alleles; 279 homozygotes)

    2. Case: P26, Chinese, female, 30yo

      DiseaseAssertion: VWD2A

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type AB blood, bleeding score = 14; VWF:Ag (%) = 11.3, VWF:RCo (%) = 3.7, FVIII:C (%) = 45.0, VWF:CB (%) = 4.0, VWFpp (%) = 41.7, VWF:RCo/VWF:Ag = 0.3, VWF:CB/VWF:Ag = 0.4, VWFpp/VWF:Ag = 3.7, FVIII:C/VWF:Ag = 4.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4517C>T (p.Ser1506Leu)

      HGVS: NM_000552.4(VWF):c.4517C>T (p.Ser1506Leu)

      ClinVarID: 100369; https://www.ncbi.nlm.nih.gov/clinvar/variation/100369/

      CAID: NA

      gnomAD: absent

    3. Case: P50, Chinese, male, 51yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type AB blood, bleeding score = 6; VWF:Ag (%) = 4.1, VWF:RCo (%) = 3.0, FVIII:C (%) = 7.8, VWF:CB (%) = 1.9, VWFpp (%) = 51.0, VWF:RCo/VWF:Ag = 0.7, VWF:CB/VWF:Ag = 0.5, VWFpp/VWF:Ag = 12.4, FVIII:C/VWF:Ag = 1.9, RIPA (1.2 mg/ml, %) = 97.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.971G>C (p.Arg324Pro)

      HGVS: NM_000552.5:c.971G>C (p.Arg324Pro)

      ClinVarID: NA

      CAID: CA383506405; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383506405

      gnomAD: absent

    4. Case: P3, Chinese, male, 7yo

      DiseaseAssertion: VWD2A

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 5; VWF:Ag (%) = 13.0, VWF:RCo (%) = 5.0, FVIII:C (%) = 39.1, VWF:CB (%) = 3.5, VWFpp (%) = 46.8, VWF:RCo/VWF:Ag = 0.4, VWF:CB/VWF:Ag = 0.3, VWFpp/VWF:Ag = 3.6, FVIII:C/VWF:Ag = 3.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4517C>T (p.Ser1506Leu)

      HGVS: NM_000552.4(VWF):c.4517C>T (p.Ser1506Leu)

      ClinVarID: 100369; https://www.ncbi.nlm.nih.gov/clinvar/variation/100369/

      CAID: NA

      gnomAD: absent

    5. Case: P43, Chinese, male, 7yo

      DiseaseAssertion: VWD2N

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 3; VWF:Ag (%) = 48.8, VWF:RCo (%) = 49.9, FVIII:C (%) = 6.4, VWF:CB (%) = 63.9, VWFpp (%) = 52.4, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 1.3, VWFpp/VWF:Ag = 1.1, FVIII:C/VWF:Ag = 0.1, VWF: FVIIIB (%) = 0.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.2372C>T (p.Thr791Met)

      HGVS: NM_000552.4(VWF):c.2372C>T (p.Thr791Met)

      ClinVarID: 294; https://www.ncbi.nlm.nih.gov/clinvar/variation/294/

      CAID: NA

      gnomAD: MAF = 0.00003984 (1/25100 alleles) in European (Finnish) population; https://gnomad.broadinstitute.org/variant/12-6153527-G-A?dataset=gnomad_r2_1

      Variant 2: c.2574C>G (p.Cys858Trp)

      HGVS: NM_000552.5:c.2574C>G (p.Cys858Trp)

      ClinVarID: NA

      CAID: CA232299278; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA232299278

      gnomAD: MAF = 0.0001002 (2/19954 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6143965-G-C

    6. Case: P73, Chinese, female, 16yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 2; VWF:Ag (%) = 29.6, VWF:RCo (%) = 35.4, FVIII:C (%) = 63.1, VWF:CB (%) = 35.0, VWFpp (%) = 78.3, VWF:RCo/VWF:Ag = 1.2, VWF:CB/VWF:Ag = 1.2, VWFpp/VWF:Ag = 2.6, FVIII:C/VWF:Ag = 2.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.2279G>A (p.Arg760His)

      HGVS: NM_000552.4(VWF):c.2279G>A (p.Arg760His)

      ClinVarID: 31011; https://www.ncbi.nlm.nih.gov/clinvar/variation/31011/

      CAID: NA

      gnomAD: MAF = 0.00008009 (2/24972 alleles) in African/African-American population; https://gnomad.broadinstitute.org/variant/12-6155891-C-T?dataset=gnomad_r2_1

    7. Case: P58, Chinese, female, 27yo

      DiseaseAssertion: VWD2A

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeText: HP:0012147

      (Reduced quantity of VWF)

      CaseNOTHPOs: type O blood, bleeding score = 8; VWF:Ag (%) = 17.1, VWF:RCo (%) = 2.3, FVIII:C (%) = 44.3, VWF:CB (%) = 3.7, VWFpp (%) = 41.1, VWF:RCo/VWF:Ag = 0.1, VWF:CB/VWF:Ag = 0.2, VWFpp/VWF:Ag = 2.4, FVIII:C/VWF:Ag = 2.6

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4790G>T (p.Arg1597Leu)

      HGVS: NM_000552.4(VWF):c.4790G>T (p.Arg1597Leu)

      ClinVarID: 100392; https://www.ncbi.nlm.nih.gov/clinvar/variation/100392/

      CAID: NA

      gnomAD: absent

    8. Case: P18, Chinese, male, 23yo

      DiseaseAssertion: VWD2A

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 7; VWF:Ag (%) = 25.0, VWF:RCo (%) = 5.2, FVIII:C (%) = 39.0, VWF:CB (%) = 6.7, VWFpp (%) = 49.6, VWF:RCo/VWF:Ag = 0.2, VWF:CB/VWF:Ag = 0.3, VWFpp/VWF:Ag = 2.0, FVIII:C/VWF:Ag = 1.6

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4735G>A (p.Gly1579Arg)

      HGVS: NM_000552.4(VWF):c.4735G>A (p.Gly1579Arg)

      ClinVarID: 100385; https://www.ncbi.nlm.nih.gov/clinvar/variation/100385/

      CAID: NA

      gnomAD: absent

    9. Case: P17, Chinese, female, 20yo

      DiseaseAssertion: VWD2M

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type B blood, bleeding score = 10; VWF:Ag (%) = 17.6, VWF:RCo (%) = 7.3, FVIII:C (%) = 35.8, VWF:CB (%) = 15.8, VWFpp (%) = 51.9, VWF:RCo/VWF:Ag = 0.4, VWF:CB/VWF:Ag = 0.9, VWFpp/VWF:Ag = 2.9, FVIII:C/VWF:Ag = 2.0

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3389G>T (p.Cys1130Phe)

      HGVS: NM_000552.4(VWF):c.3389G>T (p.Cys1130Phe)

      ClinVarID: 100261; https://www.ncbi.nlm.nih.gov/clinvar/variation/100261/

      CAID: NA

      gnomAD: absent

    10. Case: P74, Chinese, female, 26yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type A blood, bleeding score = 10; VWF:Ag (%) = 4.7, VWF:RCo (%) = 4.1, FVIII:C (%) = 31.0, VWF:CB (%) = 3.6, VWFpp (%) = 5.2, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 0.8, VWFpp/VWF:Ag = 1.1, FVIII:C/VWF:Ag = 6.6, RIPA (1.2 mg/ml, %) = 93.4

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.-1+3A>C

      HGVS: NA

      ClinVarID: NA

      CAID: NA

      gnomAD: NA

      Variant 2: c.3322G>C (p.Ala1108Pro)

      HGVS: NM_000552.3:c.3322G>C (p.Ala1108Pro)

      ClinVarID: NA

      CAID: CA383512138; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383512138

      gnomAD: absent

    11. Case: P23, Chinese, female 23

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 14; VWF:Ag (%) = 1.0, VWF:RCo (%) = 0.9, FVIII:C (%) = 4.7, VWF:CB (%) = 0.8, VWFpp (%) = 0.7, VWF:RCo/VWF:Ag = 0.9, VWF:CB/VWF:Ag = 0.8, VWFpp/VWF:Ag = 0.8, FVIII:C/VWF:Ag = 5.6

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.7361C>A (p.Thr2454Asn)

      HGVS: NM_000552.5:c.7361C>A (p.Thr2454Asn)

      ClinVarID: NA

      CAID: CA6401695; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA6401695

      gnomAD: MAF = 0.0003263 (6/18390 alleles) in the East Asian population; https://gnomad.broadinstitute.org/variant/12-6085353-G-T

    12. Case: P90, Chinese, female, 30yo

      DiseaseAssertion: VWD2A

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 12; VWF:Ag (%) = 10.1, VWF:RCo (%) = 3.3, FVIII:C (%) = 10.7, VWF:CB (%) = 2.6, VWFpp (%) = 151.7, VWF:RCo/VWF:Ag = 0.3, VWF:CB/VWF:Ag = 0.3, VWFpp/VWF:Ag = 15.0, FVIII:C/VWF:Ag = 1.1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.1730-2A>G

      HGVS: NM_000552.4(VWF):c.1730-2A>G

      ClinVarID: 100189; https://www.ncbi.nlm.nih.gov/clinvar/variation/100189/

      CAID: NA

      gnomAD: absent

      Variant 2: c.6979T>A (p.Cys2327Ser)

      HGVS: NM_000552.3:c.6979T>A (p.Cys2327Ser)

      ClinVarID: NA

      CAID: CA383492042; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383492042

      gnomAD: absent

    13. Case: P38, Chinese, female, 14yo

      DiseaseAssertion: VWD3

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 9; VWF:Ag (%) = 1.3, VWF:RCo (%) = 1.0, FVIII:C (%) = 4.5, VWF:CB (%) = 0.7, VWFpp (%) = 0.8, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 0.5, VWFpp/VWF:Ag = 0.6, FVIII:C/VWF:Ag = 3.5

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.2684A>G (p.Gln895Arg)

      HGVS: NM_000552.5:c.2684A>G (p.Gln895Arg)

      ClinVarID: NA

      CAID: CA383519914; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383519914

      gnomAD: NA

      Variant 2: c.3043G>T (p.Glu1015Ter)

      HGVS: NM_000552.5:c.3043G>T (p.Glu1015Ter)

      ClinVarID: NA

      CAID: CA383514739; http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383514739

      gnomAD: absent

    14. Case: P66, Chinese, male, 27yo

      DiseaseAssertion: VWD1

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147

      (Reduced quantity of VWF)

      CaseHPOFreeText: type O blood, bleeding score = 1; VWF:Ag (%) = 56.0, VWF:RCo (%) = 43.4, FVIII:C (%) = 70.0, VWF:CB (%) = 58.9, VWFpp (%) = 53.6, VWF:RCo/VWF:Ag = 0.8, VWF:CB/VWF:Ag = 1.1, VWFpp/VWF:Ag = 1.0, FVIII:C/VWF:Ag = 1.3

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NGS

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4414G>C (p.Asp1472His)

      HGVS: NM_000552.4(VWF):c.4414G>C (p.Asp1472His)

      ClinVarID: 256679; https://www.ncbi.nlm.nih.gov/clinvar/variation/256679/

      CAID: NA

      gnomAD: MAF = 0.5077 (12039/23712 alleles; 3078 homozygotes) in African/African-American population; https://gnomad.broadinstitute.org/variant/12-6128170-C-G?dataset=gnomad_r2_1

    1. Case#: 37006, Age 45, Female, Blood Type B+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is the only member of Family#3706.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: VWF:Ag:7.6, VWF:RCo:5, FVIII:C: 8.9, VWF:CB: 6.9

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Bleeding Score 5

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.3426T>C (p.Cys1142=), NM_000552.4:c.3614G>A (p.Arg1205His), NM_000552.4:c.7771-49G>A , NM_000552.4:c.3485_3486delinsTG (pPro1162Leu)

      ClinVar: 256668 , 308, 619934 ClinVar1 ClinVar2 ClinVar3

      CAID: CA6402757, CA114160, CA1139532197, and CA658683073 CAID1 CAID2 CAID3 CAID4

      gnomAD: MAF of 0.2228 (2240/ 10052 alleles) in the African population (CA6402757). gnomAD

    2. Case#: 35004, Age 16, Male, Blood Type A+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is one of 4 members of Family# 3501. All members have the same variants, and patient 35001 has an additional variant.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 6, VWF:Ag: 5.6, VWF:RCo: 7.9, FVIII:C: 19, VWF:CB: 7.8

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.3:c.5198T>C (p.Leu1733Pro) and NM_000552.4:c.6187C>T (p.Pro2063Ser)

      ClinVar: 100436 ClinVar

      CAID: CA383496267 and CA202650 CAID1 CAID2

      gnomAD: MAF of 0.04854 (1486/ 30616 alleles) in the South Asian population (CA202650). gnomAD

    3. Case#: 01028, Age 8, Male, Blood type O+( Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: Not listed

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding score 7, VWF:Ag: 21, VWF:RCo: 33, FVIII:C: 34, VWF:CB: 30

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.4751A>G (p.Tyr1584Cys) and NM_000552.3:c.5312-19A>C

      ClinVar: 310 and 806794

      ClinVar1

      ClinVar2

      CAID: CA114162 and CA6402297 CAID1 CAID2

      gnomAD: MAF of 0.004024 (519/128972 alleles) in the European (non-Finnish) population (CA114162). MAF of 0.002507 (26/10370 alleles) in the Ashkenazi Jewish population.

      gnomAD1

      gnomAD2

    4. Case#: 23013, Age 46, Female, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is the member of Family #2309.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 0, VWF:Ag: 33, VWF:RCo: 27.5, FVIII:C:56, VWF:CB:26

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: NM_000552.4:c.6911G>A (p.Cys2304Tyr)

      ClinVar: 100451 ClinVar

      CAID: CA228762 CAID

      gnomAD: N/A

    5. Case#: 10003, Age 33, Male, Blood Type A+ (Table S3)

      Disease Assertion: VWD1

      FamilyInfo: The patient and one other patient are members of Family#1002. The second member has the same exonic variant and also has an intronic variant.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 1, VWF:Ag:7.4, VWF:RCo: 7.2, FVIII:C:11, VWF:CB: 6.3

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: NM_000552.4:c.3614G>A (p.Arg1205His)

      ClinVar: 308 ClinVar

      CAID: CA114160 CAID

      gnomAD: N/A

    6. Case#: 22006, Age 58, Male, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is one of 2 patients in Family# 2206. Patient 22007's variant information was not described.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 7, VWF:Ag: 27, VWF:RCo: 20, FVIII:C: 12, VWF:CB:22

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant:NM_000552.4:c.1001G>A (p.Gly334Glu) and NM_000552.4(VWF):c.2561G>A (p.Arg854Gln)

      ClinVar: 626947 and 296 ClinVar1 ClinVar2

      CAID: CA232322015 and CA114139 CAID1 CAID2

      gnomAD: MAF of 0.000008824 (1/11326 alleles) in the European (non-Finnish) population (CA232322015). gnomAD1

      MAF of 0.005692 (143/25122 alleles) in the European (Finnish) population (CA114139). gnomAD2

    7. Case#: 13010, Age 37, Female, Blood Type O+ (Table S3)

      Disease Assertion: VWD1

      FamilyInfo: The patient is one of two members of Family#1308. Patient 13011 has one of the same exonic variant but has one different exonic variant (c.546G>A).

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding Score 18, VWF:Ag:16, VWF:RCo:15.1, FVIII:C:45, VWF:CB14

      CaseNotHPOs: N/A

      CaseNotHPOFreeText:N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: NM_000552.4:c.1472G>C(p.Arg491Pro) and NM_000552.4:c.546G>A (p.=)

      ClinVar: 256684 ClinVar

      CAID: CA383500718 and CA6403759 [CAID1] (http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA383500718)

      CAID2

      gnomAD: MAF of 0.002398 (85/35440 alleles) in the Latino population (CA6403759).

      gnomAD

    8. Case#: 30037, Age 69, Male, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is the only member of Family# 3013

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: VWF:Ag: 20, VWF:RCo: 17, FVIII:C: 25, VWF:CB: 13

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Bleeding Score 1

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations.

      Gene: VWF

      Variant: NM_000552.4:c.5336G>T (p.Arg1779Leu)

      ClinVar: N/A

      CAID: CA383495656 CAID

      gnomAD:MAF of 0.00002891 (1/ 34592 alleles) in the Latino population. gnomAD

    9. Case#: 13012, Age 42, Male, Blood Type A+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is the only member of Family#1309.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding score 7, VWF:Ag:14, VWF:RCo:9, FVIII:C: 20, VWF:CB:11

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: NM_000552.4:c.3614G>A (p.Arg1205His) and

      ClinVar: 308 ClinVar

      CAID: CA114160 and CA6403769 CAID1 CAID2

      gnomAD: MAF of 0.0005784 (20/34578 alleles) in the Latino population (CA6403769). gnomAD

    10. Case#: 21023, Age 43, Female, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is the only member of Family #2120.

      Parental Genotype: Not listed

      CasePresentingHPOs: N/A

      CaseHPOFreeText: VWF:Ag:7.6, VWF:RCo:6, FVIII:C: 11, VWF:CB:3.9

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Bleeding Score 2

      Protein Expression: N/A

      CasePreviousTesting: 48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant: NM_000552.4:c.1110-26T>A (p.=) , NM_000552.4:c.2103C>T (p.Cys701=), and NM_000552.4:c.6248G>A (p.Gly2083Asp)

      ClinVar: 310076 ClinVar1

      CAID: CA6403542 , CA6403175, and CA383492072 CAID1 CAID2 CAID3

      gnomAD: MAF of 0.008911 (222/ 24914 alleles) in the African population (CA6403542). MAF of 0.005928 (148/ 24968 alleles) in the African population (CA6403175). gnomAD1

    11. Case#: 23012, Age 32, Female, Blood Type O+ (Table S3)

      Disease Assertion: VWD 1

      FamilyInfo: The patient is one of two members of Family# 2308. Patient 23011 has an additional exonic variant.

      Parental Genotype: Not listed

      CasePresentingHPOs:N/A

      CaseHPOFreeText: Bleeding score 12, VWF:Ag:7, VWF:RCo:5.3, FVIII:C:6.5, VWF:CB:6

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Protein Expression: N/A

      CasePreviousTesting:48,48 Access-Array amplification. NGS Molecular analysis was performed. Sanger sequencing was used to validate selected mutations

      Gene: VWF

      Variant:NM_000552.4:c.3614G>A (p.Arg1205His)

      ClinVar: 308 ClinVar

      CAID:CA114160 CAID

      gnomAD: N/A

    1. 1 A

      Case: Patient 1, Family A (Table 1.), F/49, Afro-Caribbean

      DiseaseAssertion: VWD2B

      FamilyInfo: Patient 2 (F/15, Afro-Caribbean) from same family A (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT = 7, FVIII:C (IU/dL) = 28, VWF:Ag (IU/dL) = 35, VWF:Act (IU/dL) = 10

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3946G > A p.(Val1316Met)

      HGVS: NM_000552.5:c.3946G>A (p.Val1316Met)

      ClinVarID: 290

      CAID: CA114127

      gnomAD:

    2. 2 A

      Case: Patient 2, Family A (Table 1.), F/15, Afro-Caribbean

      DiseaseAssertion: VWD2B

      FamilyInfo: Patient 1 (F/49, Afro-Caribbean) from same family G. (Table 1.)

      ParentalGenotype(s): NA

      CasePresentingHPOs:

      CaseHPOFreeRext: BAT = 3, FVIII:C (IU/dL) = 50, VWF:Ag (IU/dL) = 57, VWF:Act (IU/dL) = 14

      CaseNOTHPOs:

      CaseNOTHPOFreeText: Blood group O+

      CasePreviousTesting:

      GenotypingMethod: All samples were analyzed by captured-based high throughput sequencing which was performed with a custom-design of the VWF gene provided by Twist BioScience (San Francisco, USA). It comprised all 52 exons, intronic flanking regions, promoter and 3’UTR region of the VWF gene. Libraries were prepared by using the Twist NGS target enrichment solution (Twist BioScience) according to the manufacturer protocol. Samples were analyzed on a NovaSeq 6000 sequencer (Illumina) with a median read depth of 2500X by using the 300-cycle S1 NovaSeq 6000seq reagent kit with 150-bp paired-end reads. The raw data were analyzed with Mutect21 and Vardict2 tools. The inhouse NGSreport software (CHU Lille) was used for data visualization, sequences check and conservation of variants with high quality metrics. In some cases, patients genomic DNA was screened for sequence variations (large deletions, insertions and duplications) by Multiplex Ligation-dependent Probe Amplification (MCR Holland).

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3946G > A p.(Val1316Met)

      HGVS: NM_000552.5:c.3946G>A (p.Val1316Met)

      ClinVarID: 290

      CAID: CA114127

      gnomAD:

    1. 20

      Case: Patient 20 (Family G), male, 58yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group B, Platelet count x103/μl = 213, PFA 100 sec = >300, SPA % = 12.6, MADR mg/mL = 0.3, VWF:Ag U/dL = 48.4, VWF:CB U/dL = 4.6, VWF:CB ratio = 0.10, VWF:RCo U/dL = 13.5, VWF:RCo ratio = 0.28, Platelet VWF U/dL = 175, FVIII U/dL = 56.4, BAT F/M = 17

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    2. 1

      Case: Patient 1 (Family A), female, 3yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group B, Platelet count x103/μl = 290, PFA 100 sec = >264, SPA % = NA, MADR mg/mL = NA, VWF:Ag U/dL = 41.0, VWF:CB U/dL = 4.4, VWF:CB ratio = 0.11, VWF:RCo U/dL = 13.2, VWF:RCo ratio = 0.33, Platelet VWF U/dL = 76.4, FVIII U/dL = 36.1, BAT F/M = NA

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    3. 8

      Case: Patient 8 (Family D), male, 49yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group A, Platelet count x103/μl = 252, PFA 100 sec = 175, SPA % = 0, MADR mg/mL = 0.6, VWF:Ag U/dL = 54.3, VWF:CB U/dL = 55.1, VWF:CB ratio = 1.01, VWF:RCo U/dL = 51.6, VWF:RCo ratio = 0.94, Platelet VWF U/dL = 60.3, FVIII U/dL = 62.2, BAT F/M = NA

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant 1: c.4135C>T (p.Arg1379Cys)

      HGVS: NM_000552.4(VWF):c.4135C>T (p.Arg1379Cys)

      ClinVarID: 100333; https://www.ncbi.nlm.nih.gov/clinvar/variation/100333/

      CAID: NA

      gnomAD: MAF = 0.00003891 (5/128500 alleles) in the European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6128449-G-A?dataset=gnomad_r2_1

      Variant 2: c.3797C>A (p.Pro1266Gln)

      HGVS: NM_000552.4(VWF):c.3797C>A (p.Pro1266Gln)

      ClinVarID: 100279; https://www.ncbi.nlm.nih.gov/clinvar/variation/100279/

      CAID: NA

      gnomAD: MAF = 0.001346 (41/30468 alleles; 2 homozygotes) in the South Asian population; https://gnomad.broadinstitute.org/variant/12-6128787-G-T?dataset=gnomad_r2_1

    4. 14

      Case: Patient 14 (Family C), male, 39yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group O, Platelet count x103/μl = 210, PFA 100 sec = >300, SPA % = 0, MADR mg/mL = 0.6, VWF:Ag U/dL = 61.3, VWF:CB U/dL = 10.4, VWF:CB ratio = 0.17, VWF:RCo U/dL = 18.5, VWF:RCo ratio = 0.3, Platelet VWF U/dL = 119, FVIII U/dL = 40.0, BAT F/M = 6

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    5. 12

      Case: Patient 12 (Family F), female, 50yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group A, Platelet count x103/μl = 204, PFA 100 sec = 91, SPA % = 10, MADR mg/mL = 0.45, VWF:Ag U/dL = 108, VWF:CB U/dL = 101.9, VWF:CB ratio = 0.94, VWF:RCo U/dL = 97.7, VWF:RCo ratio = 0.91, Platelet VWF U/dL = 136.4, FVIII U/dL = 107.5, BAT F/M = 16

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3797C>A (p.Pro1266Gln)

      HGVS: NM_000552.4(VWF):c.3797C>A (p.Pro1266Gln)

      ClinVarID: 100279; https://www.ncbi.nlm.nih.gov/clinvar/variation/100279/

      CAID: NA

      gnomAD: MAF = 0.001346 (41/30468 alleles; 2 homozygotes) in the South Asian population; https://gnomad.broadinstitute.org/variant/12-6128787-G-T?dataset=gnomad_r2_1

    6. 2

      Case: Patient 2 (Family A), male, 78yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group O, Platelet count x103/μl = 119, PFA 100 sec = >300, SPA % = 7, MADR mg/mL = 0.75, VWF:Ag U/dL = 44.7, VWF:CB U/dL = 11.8, VWF:CB ratio = 0.27, VWF:RCo U/dL = 28.4, VWF:RCo ratio = 0.63, Platelet VWF U/dL = 115, FVIII U/dL = 48.2, BAT F/M = 1

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    7. 5

      Case: Patient 5 (Family C), female, 50yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group O, Platelet count x103/μl = 211, PFA 100 sec = 210, SPA % = 10, MADR mg/mL = 0.6, VWF:Ag U/dL = 40.6, VWF:CB U/dL = 42.8, VWF:CB ratio = 1.1, VWF:RCo U/dL = NA, VWF:RCo ratio = NA, Platelet VWF U/dL = 41.2, FVIII U/dL = 62.8, BAT F/M = 8

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4135C>T (p.Arg1379Cys)

      HGVS: NM_000552.4(VWF):c.4135C>T (p.Arg1379Cys)

      ClinVarID: 100333; https://www.ncbi.nlm.nih.gov/clinvar/variation/100333/

      CAID: NA

      gnomAD: MAF = 0.00003891 (5/128500 alleles) in the European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6128449-G-A?dataset=gnomad_r2_1

    8. 18

      Case: Patient 18 (Family E), female, 1yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group O, Platelet count x103/μl = 28, PFA 100 sec = >300, SPA % = NA, MADR mg/mL = NA, VWF:Ag U/dL = 142.9, VWF:CB U/dL = 97.0, VWF:CB ratio = 0.68, VWF:RCo U/dL = 102.7, VWF:RCo ratio = 0.72, Platelet VWF U/dL = 135, FVIII U/dL = 98.1, BAT F/M = NA

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3946G>A (p.Val1316Met)

      HGVS: NM_000552.4(VWF):c.3946G>A (p.Val1316Met)

      ClinVarID: 290; https://www.ncbi.nlm.nih.gov/clinvar/variation/290/

      CAID: NA

      gnomAD: absent

    9. 12

      Case: Patient 12 (Family C), female, 60yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group O, Platelet count x103/μl = 154, PFA 100 sec = >300, SPA % = NA, MADR mg/mL = 0.75, VWF:Ag U/dL = 44.6, VWF:CB U/dL = 8.1, VWF:CB ratio = 0.18, VWF:RCo U/dL = 23.0, VWF:RCo ratio = 0.51, Platelet VWF U/dL = 127, FVIII U/dL = 68.0, BAT F/M = 18

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3922C>T (p.Arg1308Cys)

      HGVS: NM_000552.4(VWF):c.3922C>T (p.Arg1308Cys)

      ClinVarID: 289; https://www.ncbi.nlm.nih.gov/clinvar/variation/289/

      CAID: NA

      gnomAD: absent

    10. 7

      Case: Patient 7 (Family C), female, 21yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group O, Platelet count x103/μl = 293, PFA 100 sec = >300, SPA % = 6, MADR mg/mL = 0.6, VWF:Ag U/dL = 26.7, VWF:CB U/dL = 27.2, VWF:CB ratio = 1.01, VWF:RCo U/dL = 25.8, VWF:RCo ratio = 0.92, Platelet VWF U/dL = 59.1, FVIII U/dL = 40.9, BAT F/M = 6

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.4135C>T (p.Arg1379Cys)

      HGVS: NM_000552.4(VWF):c.4135C>T (p.Arg1379Cys)

      ClinVarID: 100333; https://www.ncbi.nlm.nih.gov/clinvar/variation/100333/

      CAID: NA

      gnomAD: MAF = 0.00003891 (5/128500 alleles) in the European (non-Finnish) population; https://gnomad.broadinstitute.org/variant/12-6128449-G-A?dataset=gnomad_r2_1

    11. 9

      Case: Patient 9 (Family D), male, 18yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group A, Platelet count x103/μl = 231, PFA 100 sec = 95, SPA % = 0, MADR mg/mL = 0.75, VWF:Ag U/dL = 151.1, VWF:CB U/dL = 175.5, VWF:CB ratio = 1.16, VWF:RCo U/dL = 153.5, VWF:RCo ratio = 0.87, Platelet VWF U/dL = 95.2, FVIII U/dL = 148.2, BAT F/M = NA

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3797C>A (p.Pro1266Gln)

      HGVS: NM_000552.4(VWF):c.3797C>A (p.Pro1266Gln)

      ClinVarID: 100279; https://www.ncbi.nlm.nih.gov/clinvar/variation/100279/

      CAID: NA

      gnomAD: MAF = 0.001346 (41/30468 alleles; 2 homozygotes) in the South Asian population; https://gnomad.broadinstitute.org/variant/12-6128787-G-T?dataset=gnomad_r2_1

    12. 16

      Case: Patient 16 (Family D), male, 67yo

      DiseaseAssertion: VWD2B

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0030132, HP:0030129, HP:0030130, HP:0011871, HP:0012147

      (Absence of large von Willebrand factor multimers, impaired ristocetin cofactor assay activity, Impaired von Willebrand factor collagen binding activity, Impaired RIPA, Reduced quantity of VWF)

      CaseHPOFreeText: blood group O, Platelet count x103/μl = 60, PFA 100 sec = >300, SPA % = 20, MADR mg/mL = 0.15, VWF:Ag U/dL = 34.3, VWF:CB U/dL = 10.5, VWF:CB ratio = 0.31, VWF:RCo U/dL = 14.0, VWF:RCo ratio = 0.41, Platelet VWF U/dL = 142.50, FVIII U/dL = 43.5, BAT F/M = 20

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: Sequencing of exon 28 of VWF

      PreviouslyPublished: NA

      Gene: VWF

      Variant: c.3946G>A (p.Val1316Met)

      HGVS: NM_000552.4(VWF):c.3946G>A (p.Val1316Met)

      ClinVarID: 290; https://www.ncbi.nlm.nih.gov/clinvar/variation/290/

      CAID: NA

      gnomAD: absent

    1. 48 2.5 M 18 c.2303G.A p.R768Q Hmz 2.5 ,1 6 - -

      Case: 48, M, 2.5 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 2.5, VWF:Ag (U/dl): <1, Bleeding Score: 6

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.2303G>A (p.Arg768Gln), Exon 18

      Homozygous

    2. 29 0.8 F 28 c.3835G.A p.V1279I Hmz 1.6 1.8 3 + +

      Case: 29, F, 0.8 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: family history of disease, Consanguinity: yes

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 1.6, VWF:Ag (U/dl): 1.8, Bleeding Score: 3

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.3835G>A (p.Val1279Ile), Exon 28

      Homozygous

    3. 55 9 F 18 c.2303G.A p.R768Q Htz 3.2 ,1 9 + -

      Case: 55, F, 9 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: family history of disease, Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 3.2, VWF:Ag (U/dl): <1, Bleeding Score: 9

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.2303G>A (p.Arg768Gln), Exon 18

      Heterozygous

    4. 66 5 F 28 c.3862C.G p.L1288V Htz 1.4 2.3 6 - -c.3931C.T p.Q1311*c.3951C.T p.A1317Ac.4027A.G p.I1343V

      Case: 66, F, 5 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 1.4, VWF:Ag (U/dl): 2.3, Bleeding Score: 6

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.3862C>G (p.Leu1288Val), Exon 28

      c.3931C>T (p.Gln1311*), Exon 28

      c.3951C>T (p.Ala1317Ala), Exon 28

      c.4027A>G (p.Ile1343Val), Exon 28

      Heterozygous

    5. 72 6 F 17 c.2208G.Tp.M736I Htz 2.5 4 4 - -

      Case: 72, F, 6 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 2.5, VWF:Ag (U/dl): 4, Bleeding Score: 4

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.2208G>T (p.Met736Ile), Exon 17

      Heterozygous

    6. 65 10 M 28 c.3789G.A p.S1263S Hmz 2.1 1.4 5 - -c.3797C.T p.P1266Lc.3835G.A p.V1279Ic.3931C.T p.Q1311*c.3951C.T p.A1317A

      Case: 65, M, 10 years, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: no family history of disease, Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: FVIII:C: (U/dl): 2.1, VWF:Ag (U/dl): 1.4, Bleeding Score: 5

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.3789G>A (p.Ser1263Ser), Exon 28

      c.3797C>T (p.Pro1266Leu), Exon 28

      c.3835G>A (p.Val1279Ile), Exon 28

      c.3931C>T (p.Gln1311*), Exon 28

      c.3951C>T (p.Ala1317Ala), Exon 28

      Homozygous

    1. proband (II-4 in Fig. 1) had melena at 50 years of age,

      Case II-4: Male, Japan, Japanese, part of Family<br /> DiseaseAssertion: VWD2M<br /> FamilyInfo: Japanese; Fig.1; epistaxis and bleeding described and highlighted in text<br /> ParentalGenotype: Consanguineous <br /> CasePresentingHPOs: HP:0002249 (melena), HP:0000421 (epistaxis), HP:0004846 (prolonged bleeding after surgery)<br /> CaseHPOFreeText: Melena at 50 years of age, Left putinamal hemorrhaging at 58 years of age, bleeding time was 30 min<br /> CaseNotHPOs:<br /> NotHPOsFreeText: platelet count, prothrombin time were normal<br /> CasePreviousTesting: Proband's VWF gene was analyzed using an enzyme-linked immunosorbent assay kit and PCR was done. Clinical bleeding expression was estimated.<br /> Gene: VWF<br /> Variant: p.Leu1733Pro mutation <br /> ClinVar:<br /> CAID:<br /> gnomAD:

    1. Case: Case 2, male, hispanic, symptom onset at birth

      DiseaseAssertion: Platelet-type VWD (PT-VWD)

      FamilyInfo: Parents were tested for platelet antigen 5a (HPA5a): mother was negative and father was positive, parents had normal VWD panels including VWF multimer and RIPA test

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0004846, HP:0000978, HP:0001873, HP:0012541, HP:0030132

      (Prolonged bleeding after surgery, easy bruising, thrombocytopenia, Cephalohematoma, Absence of large von Willebrand factor multimers)

      CaseHPOFreeText: peripheral blood smear showed platelet clumping and large granular platelets, Platelet (×109/L) = 61, Factor VIII (IU/mL) = 0.94, VWF:Ag (IU/mL) = 0.88, VWF:RCo (IU/mL) = 0.34, VWF:CB (IU/mL) = ND, RCo/Ag ratio = 0.39, CB/Ag ratio = NA, VWF: HMW Multimers = absent

      CaseNOTHPOs: NA

      CaseNOTHPOFreeText: umbilical cord bleeding, bleeding after heel stick

      CasePreviousTesting: no mutations in exon 28 of VWF gene

      GenotypingMethod: NA

      PreviouslyPublished: NA

      Gene: GP1BA

      Variant: c.763A>G (p.Met255Val)

      HGVS: NM_000173.7(GP1BA):c.763A>G (p.Met255Val)

      ClinVarID: 4155; https://www.ncbi.nlm.nih.gov/clinvar/variation/4155/

      CAID:

      gnomAD: absent

    2. Case: Case 3, female

      DiseaseAssertion: Platelet-type VWD (PT-VWD)

      FamilyInfo: NA

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0000978, HP:0000421, HP:0000132, HP:0004846, HP:0001873, HP:0030129, HP:0030132

      (easy bruising, epistaxis, Menorrhagia, Prolonged bleeding after surgery, thrombocytopenia, Impaired ristocetin cofactor assay activity, Absence of large von Willebrand factor multimers)

      CaseHPOFreeText: pregnancy complicated by progressive thrombocytopenia; Platelet (×109/L) = 135, Factor VIII (IU/mL) = 0.78, VWF:Ag (IU/mL) = 0.69, VWF:RCo (IU/mL) = 0.22, VWF:CB (IU/mL) = ND, RCo/Ag ratio = 0.32, CB/Ag ratio = ND, VWF: HMW Multimers = absent

      CaseNOTHPOs: NA

      CaseNOTHPOFreeText: NA

      CasePreviousTesting: NA

      GenotypingMethod: NA

      PreviouslyPublished: NA

      Gene: GP1BA

      Variant: c.746G>T (p.Gly249Val)

      HGVS: NM_000173.7(GP1BA):c.746G>T (p.Gly249Val)

      ClinVarID: 4153; https://www.ncbi.nlm.nih.gov/clinvar/variation/4153/

      CAID:

      gnomAD: absent

    3. Case: Case 1, male, 13yo at assessment, symptom onset at 45 days old

      DiseaseAssertion: Platelet-type VWD (PT-VWD)

      FamilyInfo: 1 symptomatic sister (menorrhagia, hemorrhagic follicular cyst); 1 asymptomatic sister; 3 brothers: twin died at 45days old due to leukemia, 1 symptomatic with daily epistaxis, 1 asymptomatic; father had bleeding symptoms; mom had severe bleeding with c-section requiring hysterectomy

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0001973, HP:0001892, HP:0000421, HP:0000979, HP:0001873, HP:0002090, HP:0000023, HP:0030132, HP:0011871

      (Autoimmune thrombocytopenia, abnormal bleeding, epistaxis, purpura, thrombocytopenia, pneumonia, inguinal hernia, Absence of large von Willebrand factor multimers, impaired RIPA)

      CaseHPOFreeText: bleeding treated with intravenous gamma-globulin (IVIg) and corticosteroids, laparoscopic splenectomy complicated by massive intraperitoneal bleeding, multiple bone marrow aspirations performed; born via c-section of twin pregnancy due to placenta previa; mepacrine uptake assay by flow cytometry was normal, Blood smear showed very large platelets with clear signs of activation and pseudopods; Platelet (×109/L) = 95, Factor VIII (IU/mL) = 1.00, VWF:Ag (IU/mL) = 1.29, VWF:RCo (IU/mL) = 0.28, VWF:CB (IU/mL) = 0.70, RCo/Ag ratio = 0.22, CB/Ag ratio = 0.54, VWF: HMW Multimers = partial loss

      CaseNOTHPOs: NA

      CaseNOTHPOFreeText: NA

      CasePreviousTesting: NA

      GenotypingMethod: NA

      PreviouslyPublished: NA

      Gene: GP1BA

      Variant: c.763A>G (p.Met255Val)

      HGVS: NM_000173.7(GP1BA):c.763A>G (p.Met255Val)

      ClinVarID: 4155; https://www.ncbi.nlm.nih.gov/clinvar/variation/4155/

      CAID:

      gnomAD: absent

    4. Case: Case 4, female, 5yo at onset, 20yo at report

      DiseaseAssertion: Platelet-type VWD (PT-VWD)

      FamilyInfo: Fhx of VWD; father diagnosed with type 2B VWD

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0000978, HP:0000421, HP:0000132, HP:0001873, HP:0004846

      (easy bruising, epistaxis, menorrhagia, thrombocytopenia, Prolonged bleeding after surgery)

      CaseHPOFreeText: pregnancy complicated by thrombocytopenia, Platelet aggregation studies were normal to ADP, epinephrine, collagen, and arachidonic; Platelet (×109/L) = 156, Factor VIII (IU/mL) = ND, VWF:Ag (IU/mL) = 0.57, VWF:RCo (IU/mL) = 0.86, VWF:CB (IU/mL) = ND, RCo/Ag ratio = 1.15, CB/Ag ratio = ND, VWF: HMW Multimers = normal

      CaseNOTHPOs: NA

      CaseNOTHPOFreeText: NA

      CasePreviousTesting: no mutations in exon 28 of the VWF gene

      GenotypingMethod: NA

      PreviouslyPublished: NA

      Gene: GP1BA

      Variant: c.746G>T (p.Gly249Val)

      HGVS: NM_000173.7(GP1BA):c.746G>T (p.Gly249Val)

      ClinVarID: 4153; https://www.ncbi.nlm.nih.gov/clinvar/variation/4153/

      CAID:

      gnomAD: absent

    1. 10 Type 2A c.3610C > T Nc.3839T > C Np.Arg1204Trpp.Phe1280Ser2728D3-E3A1htzhtzMissenseMissensena 26 14 34

      Case: 10 (also in (also in row 10 table 6)

      DiseaseAssertion: type 2A VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 26; VWF:Ac [IU/dL] = 14; FVIII:C [IU/dL] = 34

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3610C>T p.Arg1204Trp

      HGVS:

      ClinVarID: 2682106

      CAID:

      gnomAD: absent

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.3839T>C p.Phe1280Ser

      CAID: CA383506874

      gonmAD: absent

    2. 8 Type2A (IIC)c.1915C>TN p.Arg639Cys 15 D2-C8-2htz Missense O 68 49 76

      Case: IP #8 (also in row 5 table 6)

      DiseaseAssertion: type 2A (IIC) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 68; VWF:Ac [IU/dL] = 49; FVIII:C [IU/dL] = 76

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.1915C>T p.Arg639Cys

      HGVS:

      ClinVarID: not found

      CAID: CA232310080

      gnomAD: 0.00001592 (24 in 1508000) no homozygotes https://gnomad.broadinstitute.org/variant/12-6056887-G-A?dataset=gnomad_r4

    3. 31

      Case: IP #31

      DiseaseAssertion: type 2A VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 14; VWF:Ac [IU/dL] = 6; FVIII:C [IU/dL] = n/a

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4151T>G p.Leu1384Arg

      HGVS:

      ClinVarID: not found

      CAID: CA383504381

      gnomAD: absent

    4. 11 U c.3586T > C p.Cys1196Arg 27 D3-TIL-3 htz Missense A/O 21/18 18/12 RCo 55 OSCA /27

      Case: IP #11 in type U VWD sub-cohort

      DiseaseAssertion: unclassified VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 18; VWF:Ac [IU/dL] = 12; FVIII:C [IU/dL] = 27

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3586T>C p.Cys1196Arg

      HGVS:

      ClinVarID: 100270

      CAID:

      gnomAD: 0.000001239 (2 in 1614220) no homozygotes https://gnomad.broadinstitute.org/variant/12-6021988-A-G?dataset=gnomad_r4

    5. 63 Type2A(IIA)c.4885G>A p.Gly1629Arg 28 A2 htz Missense B 45 8GPIbR 36

      Case: IP #63

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032440 - blood group B

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 45; VWF:Ac [IU/dL] = 8; FVIII:C [IU/dL] = 36

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4885G>A p.Gly1629Arg

      HGVS:

      ClinVarID: 100398

      CAID:

      gnomAD: absent

    6. 8 c.4105T > A p.Phe1369Ile 28 A1 htz Missense na 30 16 61 CSA 43

      Case: IP #8 in type 2M VWD sub-cohort

      DiseaseAssertion: type 2M VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 30; VWF:Ac [IU/dL] = 16; FVIII:C [IU/dL] = 61; VWF:CB (IU/dL) = 43

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4105T>A p.Phe1369Ile

      HGVS:

      ClinVarID: 100326

      CAID:

      gnomAD: 0.000006197 (10 in 1613726) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019313-A-T?dataset=gnomad_r4

    7. 6 Type2A (IIC)c.1835T>GN p.Val612Gly 15 D2-C8-2hmz Missense O 63 39RCo 88

      Case: IP #6 (also in row 3 table 6)

      DiseaseAssertion: type 2A (IIC) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 63; VWF:Ac [IU/dL] = 39; FVIII:C [IU/dL] = 88

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.1835T>G p.Val612Gly

      HGVS:

      ClinVarID: not found

      CAID: CA383497104

      gnomAD: 0.000001298 (2 in 1541314) no homozygotes https://gnomad.broadinstitute.org/variant/12-6056967-A-C?dataset=gnomad_r4

    8. 38 U (2A/2B) c.4373G > A p.Cys1458Tyr 28 A2 htz Missense 19 1 RCo 27

      Case: IP #38 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2B) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 19; VWF:Ac [IU/dL] = 1; FVIII:C [IU/dL] = 27

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4373G>A p.Cys1458Tyr

      HGVS:

      ClinVarID: 100351

      CAID:

      gnomAD: absent

    9. 21 Type2A (IIE)c.3469T>GN p.Cys1157Gly 26 D3-TIL-3htz Missense na 27 22RCo 57

      Case: IP #21 (also in row 9 table 6)

      DiseaseAssertion: type 2A (IIE) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 27; VWF:Ac [IU/dL] = 22; FVIII:C [IU/dL] = 57

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3469T>G p.Cys1157Gly

      HGVS:

      ClinVarID:

      CAID: CA383511299

      gnomAD: absent

    10. 5 U (2A/1) c.3389G > Ac.3539–10T > G Np.Cys1130Tyr-2626D3-TIL-3D3-TIL-3htzhtzMissenseSplice Sitena 17 16 20

      Case: IP #5 in type U VWD sub-cohort (also in row 3 splice variants table 6)

      DiseaseAssertion: unclassified (2A/1) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs:

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 17; VWF:Ac [IU/dL] = 16; FVIII:C [IU/dL] = 20

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.3389G>A

      HGVS:

      ClinVarID: 1684001

      CAID:

      gnomAD: absent

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.3539–10T>G

      ClinVarID: not found

      **gnomAD: absent

    11. 31 U (2A/2M/1C) c.4120C > T p.Arg1374Cys C 28 A1 htz Missense A/A/A/A/O/na/O/A22/ 22/23 /18/11/21/20/3210/8/6/12/4/9/11/1440 CSA /26 CSA /23 CSA /22 CSA /11 CSA /42 CSA /27 CSA /43

      Case: IP #31 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2M/1C) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 32; VWF:Ac [IU/dL] = 14; FVIII:C [IU/dL] = 43

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4120C>T p.Arg1374Cys

      HGVS:

      ClinVarID: 100329

      CAID:

      gnomAD: absent

    12. 34 U (2A/2M/1C) c.4121G > A p.Arg1374His 28 A1 htz Missense A 19 6 38

      Case: IP #34 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2M/1C) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 19; VWF:Ac [IU/dL] = 6; FVIII:C [IU/dL] = 38

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4121G>A p.Arg1374His

      HGVS:

      ClinVarID: 100330

      CAID:

      gnomAD: 0.000001239 (2 in 1613878) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019297-C-T?dataset=gnomad_r4

    13. 3 U (2A/2M/1C) C.2771G > Ac.3943C > Tp.Arg924Glnp.Arg1315Cys2128D3-VWD3A1htzhtzMissenseMissenseA 13 8 22

      Case: IP #3 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2M/1C) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 13; VWF:Ac [IU/dL] = 8; FVIII:C [IU/dL] = 22

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.2771G>A p.Arg924Gln

      HGVS:

      ClinVarID: 100240

      CAID:

      gnomAD: 0.01774 (28642 in 1614096) 297 homozygotes https://gnomad.broadinstitute.org/variant/12-6031493-C-T?dataset=gnomad_r4

      MultipleGeneVariants:

      Gene: VWF

      Variant: c.3943C>T p.Arg1315Cys

      **ClinVarID: 100310

      gnomAD: 6.196e-7 (1 in 1613892) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019475-G-A?dataset=gnomad_r4

    14. 24–31 U (2A/2M/1C) c.4120C > T p.Arg1374Cys C 28 A1 htz Missense A/A/A/A/O/na/O/A22/ 22/23 /18/11/21/20/3210/8/6/12/4/9/11/1440 CSA /26 CSA /23 CSA /22

      Case: IP #27 in type U VWD sub-cohort

      DiseaseAssertion: unclassified (2A/2M/1C) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032370 - blood group A

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 18; VWF:Ac [IU/dL] = 12; FVIII:C [IU/dL] = 22

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4120C>T p.Arg1374Cys

      HGVS:

      ClinVarID: 100329

      CAID:

      gnomAD: absent

    15. 51-54Type2A(IIA)c.4811T>AN p.Val1604Asp 28 A2 htz Missense O/A/O/O27/24/35/328/9/11/755CSA/57CSA/62

      Case: IP #53 (also in row 21 table 6)

      DiseaseAssertion: type 2A (IIA) VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442 - blood group O

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 35; VWF:Ac [IU/dL] = 11; FVIII:C [IU/dL] = 62

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4811T>A p.Val1604Asp

      HGVS:

      ClinVarID: not found

      CAID: CA383499144

      gnomAD: absent

    16. 2 2N/1 c.1117C > Tc.2561G > Ap.Arg373p.Arg854Gln1020D1-E1D’-E’htzhtzNonsenseMissenseB 43 na 10

      Case: IP #2 in type 2N VWD sub-cohort

      DiseaseAssertion: type 2N VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032440 - blood group B

      CaseHPOFreeRext: VWF:Ag [IU/dL] = 43; VWF:Ac [IU/dL] = n/a; FVIII:C [IU/dL] = 10

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: Sequence variations in the VWF were identified through direct sequencing, while the detection of large rearrangements utilized the multiplex ligation-dependent probe amplification (MLPA) technique or assessed copy number variations (CNVs). Sanger sequencing methodology was applied for VWF analysis in patients investigated prior to 2016 (approximately 14% of IPs), whereas next-generation sequencing (NGS) was employed for the analysis of VWF in patients inspected from 2017 onwards (about 86% of IPs). In both strategies, the entire VWF, encompassing all 52 exons, intron/exon boundaries, and promoter regions, was analyzed.

      PreviouslyPublished:

      Gene: VWF

      Variant: c.1117C>T p.Arg373*

      HGVS:

      ClinVarID: 100175

      CAID:

      gnomAD: 0.000008055 (13 in 1614004) no homozygotes https://gnomad.broadinstitute.org/variant/12-6071336-G-A?dataset=gnomad_r4

      **MultipleGeneVariants:

      Gene: VWF

      Variant: c.2561G>A p.Arg854Gln

      ClinVarID: 296

      gnomAD: 0.004956 (8000 in 1614214) 26 homozygotes https://gnomad.broadinstitute.org/variant/12-6034812-C-T?dataset=gnomad_r4

    1. Case UZ043: 8 year old male (row 44 supplemental table)

      DiseaseAssertion: type 2B VWD

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: HP:0032442

      CaseHPOFreeRext: vWF:Ag (%) = 29.3; vWF:GPIbR (%) = 13.6; Act/Ag ratio = 0.46; FVIII:C (%) = 68.1; Platelets (x10^9/L) = 176

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting: The Thrombosis-Hemostasis gene panel test used whole exome sequencing and included 99 diagnostic-grade genes (table 1 in PMID:36696193)

      GenotypingMethod: WES using the coagulation subpanel of the UZ Leuven Thrombosis-Haemostasis gene panel test. WES was performed on the sequencing platform NovaSeq 6000 (Illumina), and Alissa Interpret software v5.2-5.4 (Agilent) was used for variant interpretation. Assessment of copy number variation was validated within the bioinformatics pipeline. The American College of Medical Genetics and Genomics and the Association of Molecular Pathology guidelines were used to classify variants as pathogenic (P), likely pathogenic (LP), a variant of uncertain significance (VUS), or (likely) benign (LB, B) variants

      PreviouslyPublished:

      Gene: VWF

      Variant: c.4021C>T p.Arg1341Trp

      HGVS:

      ClinVarID: 100316

      CAID:

      gnomAD: 0.00001859 (30 in 1613842) no homozygotes https://gnomad.broadinstitute.org/variant/12-6019397-G-A?dataset=gnomad_r4

    1. Case#: Iannuzzi_1991_IV-1, M, age unknown, origin unknown

      DiseaseAssertion: VWD type 2A

      FamilyInfo: Affected mother, aunt, grandfather, and many other relatives. LOD score 3.61 reported (12 affected and genotype positive, 4 unaffected genotype positive. 4 affected also have HTT with vWD.

      ParentalGenotype:

      CasePresentingHPOs: As reported elsewhere (Hanna etal1984), the diagnosis of typeII AvWD was based on the following: bleedingtime, FVIII procoagulant activity, vFW:Ag, ristocetincofactoractivity, platelet aggregation studies, and vWF multimer analysis

      CaseHPOFreeText:

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: PCR-RFLP of exon 28 of VWF

      Gene: VWF

      Variant:

      HGVS: NM_000552.5(VWF):c.4883T>C (p.Ile1628Thr)

      ClinVarID: 284

      CAID:

      gnomAD: not reported

      MultipleGeneVariants:

    1. III : 3

      Case#: F10, III:3

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: complete loss of high MWM, VWF:Ag = 25; VWF:RCo = 6; VWF:GPIbM = 17; 0.23; 0.67; 2.95

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[R1306W];[=]

      HGVS: c.3916C>T (p.Arg1306Trp)

      CAID: CA114123

      gnomAD: absent from gnomad v4.1.0

    2. I : 3

      Case#: F10, I:3

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: complete loss of high MWM, VWF:Ag = 50; VWF:RCo = 6; VWF:GPIbM = 29; 0.12; 0.58; 4.82

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[R1306W];[=]

      HGVS: c.3916C>T (p.Arg1306Trp)

      CAID: CA114123

      gnomAD: absent from gnomad v4.1.0

    3. I : 1

      Case#: F10, I:1

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: complete loss of high MWM, VWF:Ag = 82; VWF:RCo = 27; VWF:GPIbM = 97; 0.33; 1.19; 3.62

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[R1306W];[=]

      HGVS: c.3916C>T (p.Arg1306Trp)

      CAID: CA114123

      gnomAD: absent from gnomad v4.1.0

    4. I : 1

      Case#: F9, I:1

      DiseaseAssertion: Type 2 VWD

      CaseHPOFreeText: complete loss of high MWM, VWF:Ag = 23; VWF:RCo = 7; VWF:GPIbM = 21; 0.29; 0.93; 3.18

      CasePreviousTesting: Not clearly described

      Gene: VWF

      Variant: p.[R1306W];[=]

      HGVS: c.3916C>T (p.Arg1306Trp)

      CAID: CA114123

      gnomAD: absent from gnomad v4.1.0

    1. 60.862.80.977141.9NormalExon 13c.1531A>C‡p.Lys511GlnD2Missense

      Case:Croatian adult patient

      DiseaseAssertion: VWD1

      ParentalGenotype(s): Not specified

      CasePresentingHPOs: HP:0001892, HP:0011890, HP:0000132, HP:0002239, HP:0000790, HP:0001342

      CaseHPOFreeText: Normal VWF:Ag of 62.8%, VWF:GPIbM of 60.8%, FVIII:C of 71% and VWF:CBA of 41.9%. Normal multimer distribution.

      CaseNOTHPOs: Not specified

      CaseNOTHPOFreeText: Normal multimer size distribution (tested in Agarose gel).

      CasePreviousTesting: Not reported

      GenotypingMethod: Illumina NGS, custom designed panel covering all 52 exons as well as intronic flanking regions and promoter region of VWF gene.

      PreviouslyPublished: None

      Gene: VWF

      Variant: c.1531A>C

      HGVS: NM_000552.4:c.1531A>C (p.Lys511Gln)

      ClinVarID: Not available

      CAID: CA383500354

      gnomAD: Not available

    2. VWD2-3†10.917.20.632110.1↓HMWM,↓IMWM28c.3829G>T§p.Asp1277TyrA1Missense2A

      Case: Croatian adult patient

      DiseaseAssertion: VWD2A

      FamilyInfo: No variant detected in a family member with VWD2

      ParentalGenotype(s): Not specified

      CasePresentingHPOs: HP:0001892, HP:0011890, HP:0000132, HP:0002239, HP:0000790, HP:0001342

      CaseHPOFreeText: Reduced VWF:Ag of 17.2%, VWF:GPIbM of 10.9%, FVIII:C of 21% and VWF:CBA of 10.1%. Reduced levels of HMWM and IMWM in multimer distribution.

      CaseNOTHPOs: Not specified

      CaseNOTHPOFreeText: Not reported.

      CasePreviousTesting: Not reported

      GenotypingMethod: Illumina NGS, custom designed panel covering all 52 exons as well as intronic flanking regions and promoter region of VWF gene.

      PreviouslyPublished: None

      Gene: VWF

      Variant: c.3829G>T

      HGVS: NM_000552.4:c.3829G>T (p.Asp1277Tyr)

      ClinVarID: Not available

      CAID: CA383506920

      gnomAD: Not available

    1. P15

      Case: P15, M/45

      DiseaseAssertion: VWD1

      FamilyInfo: Positive family history, no details provided.

      ParentalGenotype: NA

      CaseHPOFreeText: The bleeding score was 11, aPTT was 59 seconds, FVIII:C was 3%, VWF:RCo was 11 IU/dL, and VWF:Ag was 6 IU/dL, with a VWF:RCo/VWF:Ag ratio of 1.8. The VWF multimer pattern was normal, RIPA was 2 ohms, and the platelet count was 378 × 10⁹/L.

      CasePreviousTesting: NA

      GenotypingMethod: Direct sequencing of all exons, flanking intronic sequences, and the promoter of VWF was performed.

      Gene: VWF

      Variant: c.2574C>G, p.C858W — heterozygous

      HGVS: NM_000552.5(VWF):c.2574C>G (p.Cys858Trp)

      ClinVar:

      CAID: CA232299278

      gnomAD: https://gnomad.broadinstitute.org/variant/chr12-6034799-G-C?dataset=gnomad_r4

    1. .3797C>Tc.3835G>A

      Case 1: Southern Spanish, unrelated patient to Case 2

      DiseaseAssertion: VWD1

      FamilyInfo: Patient unrelated to families of Case 2, but same two VWF variants found on the same allele

      CasePresentingHPOs4: Not reported

      CaseHPOFreeText4: Bleeding score of 4

      CaseNotHPOs: Not reported

      CaseNotHPOFreeText: Normal multimeric assay, VWF:Ag level at 66%, VWF:RCo at 60 U/mL, FVIIIC at 84 U/dL, VWF:RCo/VWF:Ag ratio of 0.9, PFA-100:Col-EPI/Col-ADP of 277s/124s

      CasePreviousTesting: Sequencing of exon 28 of VWF gene in 11 families.

      Gene: VWF

      Variant: c.3797C>T, c.3835G>A

      ClinVarID:314, 100288

    1. 0.45

      Case: 2A-2

      DiseaseAssertion: VWD2A

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: AcuStar RCo/Ag = 0.45; AcuStar CB/Ag = 0.26; ELISA CB/Ag = 0.30

      CaseHPOFreeText:

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: not described

      PreviouslyPublished: PMID: 8435341

      Gene: VWF

      Variant: c.4541T>G (p.Phe1514Cys)

      HGVS: NM_000552.5(VWF):c.4541T>G (p.Phe1514Cys)

      ClinVarID: 304; https://www.ncbi.nlm.nih.gov/clinvar/variation/304/?new_evidence=false

      CAID:

      gnomAD: absent

    2. 0.70

      Case: 2B-11

      DiseaseAssertion: VWD2B

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: AcuStar RCo/Ag = 0.70; AcuStar CB/Ag = 0.83; ELISA CB/Ag = 1.07

      CaseHPOFreeText:

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: not described

      PreviouslyPublished: 11325649

      Gene: VWF

      Variant: c.4135C>T (p.Arg1379Cys)

      HGVS: NM_000552.5(VWF):c.4135C>T (p.Arg1379Cys)

      ClinVarID: 100333; https://www.ncbi.nlm.nih.gov/clinvar/variation/100333/?new_evidence=false

      CAID:

      gnomAD: MAF (European, non-Finnish) = 0.00003891; 0 homozygotes; https://gnomad.broadinstitute.org/variant/12-6128449-G-A

    3. 0.66

      Case: 2B-6

      DiseaseAssertion: VWD2B

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: AcuStar RCo/Ag = 0.66; AcuStar CB/Ag = 0.69; ELISA CB/Ag = 0.71

      CaseHPOFreeText:

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: not described

      PreviouslyPublished: 1373334

      Gene: VWF

      Variant: c.4010C>T (p.Pro1337Leu)

      HGVS: NM_000552.5(VWF):c.4010C>T (p.Pro1337Leu)

      ClinVarID: 100314; https://www.ncbi.nlm.nih.gov/clinvar/variation/100314/?new_evidence=false

      CAID:

      gnomAD: MAF = 0.00005440 in East Asian population; https://gnomad.broadinstitute.org/variant/12-6128574-G-A

    4. 1

      Case: 2M-1

      DiseaseAssertion: VWD2M

      FamilyInfo:

      ParentalGenotype(s):

      CasePresentingHPOs: AcuStar RCo/Ag = 0.60; AcuStar CB/Ag = 1.16; ELISA CB/Ag = 1.12

      CaseHPOFreeText:

      CaseNOTHPOs:

      CaseNOTHPOFreeText:

      CasePreviousTesting:

      GenotypingMethod: not described

      PreviouslyPublished:

      Gene: VWF

      Variant: p.Arg1315Gln

      HGVS: n/a

      ClinVarID: n/a

      CAID: n/a

      gnomAD: n/a

    1. III-1

      III-1, Female 10 years old

      disease assertion: VWD

      **positive family history **

      Parental Genotype: each has heterozygous, 3251G>A

      CasePresentingHPOs: CaseHPOFreeText: BS 4, VWF Ag:0.38, *VWF:GPIbM:0.15,VWF:CB:0.13, VWFpp :0.76, FVIII:C:0.10

      CaseNOTHPOs:* N.a.

      CaseNOTHPOFreeText: n.a.

      CasePreviousTesting: *GenotypingMethod: Sanger seqencing;

      *PreviouslyPublished:n.a.

      Gene:VWF Variant:c.3251G>A*

      *HGVS:NM_000552.5:c.3251G>A

      • *ClinVarID:Variation ID: 626952

      *CAID:n.a.

      *gnomAD:n.a.

    1. A case report of type 2M Von Willebrand disease withunique mutations

      Gene: VWF

      HGNCID: 12726

      Case: 55 year old female

      DiseaseAssertion: type 2M VWD

      FamilyInfo: one sister with VWD of unknown type. Four other siblings with no bleeding history.

      CasePresentingHPOs: HP:0002239 (Gastrointestinal hemorrhage), Gastrointestinal angiodysplasia HP:0000471, Hemoptysis HP:0002105, Epistaxis HP:0000421, Menorrhagia HP:0000132

      CaseHPOFreeRext: normal PT/aPTT. Von Willebrand panel shows vWF antigen of 33%, VWF ristocetin cofactor activity of 15%, and Factor VIII of 87%. The ratio (VWF: RCo/VWF: Ag) is low (0.45) and the multimer pattern is normal.

      Gene: VWF

      Variant: c.4241T>G (p.Val1414Gly) and c.5227G>A (p.Val1743Met)

      ClinVarID: 619752, 801307

    1. Case#: Kumar_2016_ , M, 9 months (report)

      DiseaseAssertion: VWD type 2B

      FamilyInfo: no family history, de novo assertion but no testing to prove it.

      ParentalGenotype: not reported

      CasePresentingHPOs:

      CaseHPOFreeText: low von Willebrand factor (vWF) antigen (32%) and ristocetin cofactor activity (<8%). loss of high-molecular-weight multimers, bruising, extensive bleeding

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: not reported

      GenotypingMethod: exon 28 sequencing

      Gene: VWF

      Variant:

      HGVS: NM_000552.5(VWF):c.3940G>C, p.V1314L

      ClinVarID: 302

      CAID:

      gnomAD: not reported

      MultipleGeneVariants:

    1. 35*IndiaM/42<1—NoMild8411G→AC2804Y52HomozygousRsaI (+)

      Case: 35, M, 42, Indian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: No

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Mild

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      8411G→A (Cys2804Tyr), Exon 52, Homozygous

      Note: It is possible that the homozygous zygosity was detected from a PCR artifact (e.g. presence of a large gene deletion or point mutation that prevents amplification); different sets of primers were used, providing conformation and excluding the possibility for a PCR artifact due to point mutation.

    2. 7*ItalyF/36<1—NoSevere2435delC/5170+10C→T 253T→CFS/FS-S85P18/29-4HeterozygousBglI (−)/N.A.

      Case: 7 , F, 36, Italian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: no

      ParentalGenotype:

      2435delC on the maternal allele

      5170+10C→T on the paternal allele

      253T→C on the paternal allele

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (U/dl): <1, Bleeding symptoms: Severe

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      2435delC (FS), Exon 18

      5170+10C→T (Intronic), Exon 29

      253T→C (Ser85Pro), Exon 4

      Compound Heterozygous

      Note: Article assumes that 5170+10C→T would be a frameshift mutation. No potential splice site mutation was confirmed at the mRNA level; “Splice Site Prediction program” found all mutations likely to disrupt normal splicing. No possible splice site mutation could be identified on 100 chromosomes from a group of 50 normal subjects with same genetic background as patients, excluding the possibility that these mutations represent common polymorphisms.

    1. T030M/6670.030.010.09c.-2328T>G, c.2220G>A, c.3379 + 7A>C, c.3539-33G>A, c.3539-49C>T, c.4414dupC, c.5620 + 33-40delA, c.6554G>A, c.6902-5T>A, c.8418_8419insTCCCp.Met740Ile, p.His1472 fs, p.Arg2185Gln, p.Ser2807 fs28/52Compound heterozygous

      Case: T030, M, 66

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 7 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.03, VWF:RCo (IU/ml): 0.01, FVIII:C (IU/ml): 0.09

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.-2328T>G

      c.2220G>A (p.Met740Ile)

      c.3379 + 7A>C

      c.3539-33G>A

      c.3539-49C>T

      c.4414dupC (p.His1472 fs)

      c.5620 + 33-40delA

      c.6554G>A (p.Arg2185Gln)

      c.6902-5T>A

      c.8418_8419insTCCC (p.Ser2807 fs)

      Exon 28/52

      Compound heterozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    2. T141F/16130.040.040.06c.817T>Cp.Arg273Trp7Homozygous

      Case: T141, F, 16

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 13 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.04, VWF:RCo (IU/ml): 0.04, FVIII:C (IU/ml): 0.06

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.817T>C (p.Arg273Trp), Exon 7, Homozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    3. T093M/8100.020.020.04c.6709T>C, c.220 + 20G>Tp.Cys2237Arg, -38Homozygous

      Case: T093, M, 8

      DiseaseAssertion: VWD type 3

      FamilyInfo: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: Bleeding Score: 10 (Kruskal–Wallis followed by Mann–Whitney U post-hoc testing Post-hoc testing ), VWF:Ag (IU/ml): 0.02, VWF:RCo (IU/ml): 0.02, FVIII:C (IU/ml): 0.04

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.6709T>C (p.Cys2237Arg), Exon 38

      c.220 + 20G>T

      Homozygous

      Note: ELISA-based assay for detecting alloantibodies, genomic analysis via sequencing of leukocytes for the VWF gene including exons 1-52 and about 1.5 km of VWF promoter, PCR amplification for variant confirmation, SALSA-MLPAVWF assay evaluation for partial/total gene deletions when sequencing did not reveal pathogenic explanation

    1. 203< 1< 16−14Mc.103T>C/c.4975C>Tp.C35R/p.R1659X3/2814/16N/PD

      Case: Patient 20, M, Hungarian

      DiseaseAssertion: VWD type 3

      FamilyInfo: compatible with recessive inheritance

      ParentalGenotype(s): n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeRext: Bleeding score: 14, VWF:Ag (IU dL−1): < 1, VWF:CB (IU dL−1): < 1, FVIII:C (IU dL−1): 6, VWF:RCo below detection limit (<10 IU dL−1), not detectable VWF on multimer gels

      CaseNOTHPOs: n/a

      CaseNOTHPOFreeText: did not become refractory to factor replacement therapy

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.103T>C (p.Cys35Arg), Exon 3

      c.4975C>T (p.Arg1659X), Exon 28

      Intron 40 VNTR 14/16

      Note: multimer electrophoresis, Recombinant VWF antigen concentrations and Collagen binding activity (VWF:CB) measured by ELISA, direct sequencing of the 51 exons and the exon‐intron boundaries, Breakpoint analysis and breakpoint‐specific PCR

    1. In family 3, the female proposita (3G)

      Case#: 3G

      DiseaseAssertion:

      FamilyInfo: Her father (3F), who reported mild bruising symptoms, and both asymptomatic younger male siblings (3H and 3J) were also investigated. All family members were found to be heterozygous for a previously described mutation in exon 30:c.5191 T → A, resulting in Ser1731Thr.

      CaseHPOFreeText4: In family 3, the female proposita (3G) presented in childhood with epistaxis and easy bruising. VWF:Ag and VWF:RCo were borderline low in 3F and 3G but normal in the asymptomatic brothers, 3H and 3J. Multimer analysis was normal in all family members tested (Figure 1). VWF:CB binding to type I collagen was reduced in all family members (CB/Ag ratio 0.4-0.7), whereas only one (3G) showed a reduction in CB:Ag ratio with type III collagen.

      CasePreviousTesting: Fifty-one primer sets were used to amplify the essential regions of VWF (52 exons, flanking intronic regions, 5′ promoter region, and the 3′ untranslated region).

      Gene: VWF

      Variant: heterozygous for a previously described mutation in exon 30:c.5191 T → A, resulting in Ser1731Thr

      HGVS: NM_000552.5(VWF):c.5191T>A (p.Ser1731Thr)

      ClinVar: 100420

      CAID: CA228704

      gnomAD: 0.004289 in middle eastern pop

    2. The proposita (2D) in family 2

      Case#: 2D

      DiseaseAssertion:

      FamilyInfo: Her son 2E had mild bruising and epistaxis.

      CaseHPOFreeText: The proposita (2D) in family 2 was investigated after a postpartum hemorrhage requiring blood transfusion. She gave a longstanding history of menorrhagia, and her calculated bleeding score was 10, the highest of all the persons in this study. VWF:Ag, VWF:RCo, and multimer analysis were all normal. VWF:CB was significantly reduced with both types I and III collagen, resulting in CB:Ag ratios of 0.2 to 0.4. Closure times in the PFA-100 were normal in 2D with both cassettes (Coll/Epi, 111 seconds; Coll/ADP, 98 seconds). The discrepant reduction in VWF:CB persisted after DDAVP administration to 2D despite normalization of both VWF:Ag and VWF:CB (samples taken 90 minutes after DDAVP administration showed VWF:Ag 191 IU/dL, VWF:CB 67 IU/dL, CB:Ag ratio = 0.35).

      CasePreviousTesting: Fifty-one primer sets were used to amplify the essential regions of VWF (52 exons, flanking intronic regions, 5′ promoter region, and the 3′ untranslated region).

      Gene: VWF

      Variant: Her and son were shown to be heterozygous for a novel mutation in exon 31:c.5347 T → G resulting in Ser1783Ala

      HGVS: NM_000552.5(VWF):c.5347T>G (p.Ser1783Ala)

      ClinVar: 31012

      CAID: CA228715

      gnomAD: 0.0006918 in south asian pop

    1. Dominant vWD Type 1 Secretion Defect (High FVIII/vWF:Ag Ratio) Caused by S2179F Mutation in D4 Domain in 3 Families With vWD SD

      Case: Proband 2 (Family 2)

      DiseaseAssertion: VWD1

      FamilyInfo: 2 family members diagnosed with VWD1

      ParentalGenotype(s): NA

      CasePresentingHPOs: HP:0012147, HP:0001892, HP:0030130, HP:0011871

      (Reduced quantity of Von Willebrand factor, Abnormal bleeding, Impaired von Willibrand factor collagen binding activity)

      CaseHPOFreeText: normal to slightly prolonged Ivy BT, FVIII:C % = 19, VWF:Ag % = 13, VWF:RCo % = 12, VIII C/vWF:AG ratio = 1.5, vWF:Rco/vWF:AG ratio = 0.9

      CaseNOTHPOs: HP:0030132

      (Absence of large von Willibrand factor multimers)

      CaseNOTHPOFreeText:

      CasePreviousTesting: NA

      GenotypingMethod: NA

      PreviouslyPublished: PMID: 11992235

      Gene: VWF

      Variant: c.6536C>T (p.Ser2179Phe)

      HGVS: NM_000552.4(VWF):c.6536C>T (p.Ser2179Phe)

      ClinVarID: 100442; https://www.ncbi.nlm.nih.gov/clinvar/variation/100442/

      CAID:

      gnomAD: absent

    1. 8 M/46 <1 7 No 19 c.4576C>Ta/c.6973T>Aa p.Q1526Xa/p.C2325Sa 28/40 Heterozygous

      Case: 8, M, 46, Italian

      DiseaseAssertion: VWD type 3

      FamilyInfo: Consanguinity: no

      ParentalGenotype: n/a

      CasePresentingHPOs: n/a

      CaseHPOFreeText: VWF:Ag (IU/dL): <1, FVIII:C (IU/dL): 7, Bleeding Score: 19

      CaseNotHPOs: n/a

      CaseNotHPOFreeText: Anti-VWF alloantibodies: no

      CasePreviousTesting: n/a

      Gene: VWF

      Variant:

      c.4576C>T (p.Gln1526X), Exon 28

      c.6973T>A (p.Cys2325Ser), Exon 40, B1 Domain

      Compound Heterozygous

    1. 2

      Case#: 2, female, 25yo

      DiseaseAssertion: VWD1

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0000421, HP:0000132, HP:0011891, HP:0004846, HP:0012147 (bruising susceptibility, epistaxis, Menorrhagia, Post-partum hemorrhage, Reduced quantity of VWF, Impaired ristocetin cofactor assay activity)

      CaseHPOFreeText: Type A blood, VWF:Ag (0·55–2 iu/ml) pre = 0·48, VWF:RCo (0·55–2 iu/ml) pre = 0·53, FVIII:C (0·55–2 iu/ml) pre = 0·25, FVIII:C/VWF:Ag ratio = 0·52, VWF:FVIII binding (>20%) = N/A, VWF:FVIII binding/VWF:Ag (>0·7) = N/A, multiple surgical interventions with VWF concentrate with adequate haemostasis

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: RFLP; confirmatory sequencing

      Gene: VWF

      Variant 1: NM_000552.4(VWF):c.2561G>A (p.Arg854Gln)

      ClinVar: 296; https://www.ncbi.nlm.nih.gov/clinvar/variation/296/

      gnomAD: MAF = 0.005692 (European Non-Finnish); https://gnomad.broadinstitute.org/variant/12-6143978-C-T

      Variant 2: N/A - stated to be a compound heterozygote for a 2N VWD and a presumed null mutation

    1. Supplementary Table S1 & S2 Proband and Variant Information:

      Case19: GT22, Male, 13, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0000225

      (Easy bruising, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.408+11C>A and NM_000419.3:c.1259T>C (p.Val420Ala)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940333 and CA399803733

      gnomAD: N/A

    2. Supplementary Table S1 & S2 Proband and Variant Information:

      Case17: GT20, Male, 28, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0005261

      (Epistaxis, hemarthrosis)

      CaseHPOFreeText: Occasional hematomas

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed 10-20% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.2800G>T (p.Val934Phe)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290946484

      gnomAD: N/A

    3. Supplementary Table S1 & S2 Proband and Variant Information:

      Case69: GT73, Female, 34 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0031364, HP:0000421, HP:0000225, HP:0000132

      (Ecchymosis, epistaxis, gingival bleeding, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed nromal to reduced αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.889G>A (p.Gly297Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623074

      gnomAD: MAF in the European (non-Finnish) population is 0.00002643 https://gnomad.broadinstitute.org/variant/17-45364547-G-A

    4. Supplementary Table S1 & S2 Proband and Variant Information:

      Case44: GT43b, Male, 11 years old, Morrocan

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected sister is 43a (See Supplementary Table S1)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000979, HP:0031364, HP:0000967, HP:0030137

      (Epistaxis, purpura, ecchymosis, petechiae, prolonged bleeding at circumcision)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.614+1G>T and NM_000212.2:c.683G>A (p.Arg228His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023344 and CA8623025

      gnomAD: MAF in the African population is 0.00008012 http://gnomad.broadinstitute.org/variant/17-45363694-G-A

    5. Supplementary Table S1 & S2 Proband and Variant Information:

      Case56: GT57, Female, 10, Argentinian/European

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000967

      (Epistaxis, petechia)

      CaseHPOFreeText: Hematomas

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.571T>G (p.Phe191Val) and NM_000419.3:c.961G>T (p.Phe191Alafs*32)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805699 and CA399804768

      gnomAD: N/A

    6. Supplementary Table S1 & S2 Proband and Variant Information:

      Case44: GT43b, Male, 11 years old, Morrocan

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected sister is 43a (See Supplementary Table S1)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000979, HP:0031364, HP:0000967

      (Epistaxis, purpura, ecchymosis, petechiae)

      CaseHPOFreeText: Lots of bleeding at circumcision

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.614+1G>T and NM_000212.2:c.683G>A (p.Arg228His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023344 and CA8623025

      gnomAD: MAF in the African population is 0.00008012 http://gnomad.broadinstitute.org/variant/17-45363694-G-A

    1. 12.

      Case12: 2 Females, age not specified "Two sisters" is what the Table mentions

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0002239

      (Gastrointestinal bleeding)

      CaseHPOFreeText: Life threatening bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting:

      Gene: ITGB3 and ITGA2B

      Variant: NM_000212.2:c.392G>C (p.Arg131Pro in ITGB3) and NM_000212.2:c.777+1G>A in ITGB3 and NM_000419.3:c.2264G>A (p.Arg755Gln) in ITGA2B

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8622954, CA8623036, CA8602771

      gnomAD: MAF in the African population 0.00006152 http://gnomad.broadinstitute.org/variant/17-45361839-G-C , MAF in Latino population 0.0006774 http://gnomad.broadinstitute.org/variant/17-45363789-G-A and MAF in Latino population 0.0001903 (p.Arg775Gln)

    2. 24.

      Case24: Male, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type 1

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Severe bleeding (See Table 1 for Clinical and Biological Data-- minimal information)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting: Sanger sequencing identified disease-causing variants in 18 out of 20 patients (Probands 6 and 14 excluded) with istoantibodies to αIIbβ3. The mutations were evenly distributed between ITGB3 and ITGA2B.

      Gene: ITGB3

      Variant: NM_000212.2:c.1619G>A (p.Gly540Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400030071

      gnomAD: N/A

    3. 10.

      Case10 : Female, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type 1

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Severe bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting: Sanger sequencing identified disease-causing variants in 18 out of 20 patients (Probands 6 and 14 excluded) with istoantibodies to αIIbβ3. The mutations were evenly distributed between ITGB3 and ITGA2B.

      Gene: ITGB3

      Variant: NM_000212.2:c.940G>T (p.Asp314Tyr)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400025612

      gnomAD: N/A

    1. patient 2

      Case#: patient 2

      DiseaseAssertion: Glanzmann thrombasthenia

      **FamilyInfo: **

      ParentalGenotype: If noted by authors, annotate with the carrier status of each parent in regards to the variant(s) identified in the proband.

      CasePresentingHPOs:

      PlateletAggregation: absent platelet integrin αIIbβ3. Monolayer of spread platelets essentially devoid of fibrinogen binding but with high CD62P expression and phosphatidylserine exposure (Figure S1). Figure 5.

      CaseHPOFreeText:

      CaseNotHPOs:

      **CaseNotHPOFreeText: **

      ProteinExpression:

      CasePreviousTesting:

      **PreviouslyPublished: **

      Gene: ITGA2B

      **HGVS: **

      **ClinVar: **

      CAID:

      **gnomAD: **

      Gene: ITGA2B

      **HGVS: ** NM_000419.5:c.2051T>G

      **ClinVar: ** 1330350

      CAID: CA399799849

      **gnomAD: **

    1. Supplemental Table S1:

      Cases26-33: Males and Females from France, Spain and Italy and ages are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mild to severe bleeding for probands

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: 8-20% αIIbβ3 expression

      PlateletAggregation: Absent platelet aggregation (all the information that is provided in Supp. Table S1)

      CasePreviousTesting: Sanger sequencing of exons, splice sites and untranslated regions of the ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.2113T>C (p.Cys705Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602816

      gnomAD: MAF in the European non finnish population is 0.000008792 https://gnomad.broadinstitute.org/variant/17-42455140-A-G

      PreviouslyPublished: PMID: 9920835, 12083483, 12424194, 25728920, 20020534

    2. Supplemental Table S1:

      Case3: Male, USA, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Severe life threatening bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: >5% αIIbβ3 expression

      PlateletAggregation: Absent platelet aggregation (all the information that is provided in Supp. Table S1)

      CasePreviousTesting: Sanger sequencing of exons, splice sites and untranslated regions of the ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1553T>A (p.Ile518Asn) and NM_000419.3:c.1946+3G>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8603038 and CA626121071

      gnomAD: MAF in the European (non-Finnish) population is 0.000008790 https://gnomad.broadinstitute.org/variant/17-42457661-A-T and MAF in the African population is 0.000 https://gnomad.broadinstitute.org/variant/17-42456008-C-A

      PreviouslyPublished: PMID: 25728920

    3. Supplemental Table S1:

      Case5: Male, India, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding from multiple sites

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: 8% αIIbβ3 expression

      PlateletAggregation: Absent platelet aggregation (all the information that is provided in Supp. Table S1)

      CasePreviousTesting: Sanger sequencing of exons, splice sites and untranslated regions of the ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1651C>T (p.Arg551Trp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802348

      gnomAD: MAF in the East Asian population is 0.00005045 https://gnomad.broadinstitute.org/variant/17-42457471-G-A

      PreviouslyPublished: PMID: 16879215

    1. Supplementary Table S1:

      Case48: GT55, Arg/Brazilian, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.647C>T (p.Ala216Val)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805506

      gnomAD: N/A

    2. Supplementary Table S1:

      Case49: GT57, Argentinian/European, gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.571T>G (p.Phe191Ala/ p.Phe191AlafsTer32) and NM_000419.3:c.961G>T (p.Gly321Trp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805699 and CA399804768

      gnomAD: N/A

    3. Supplementary Table S1:

      Case30: GT35a, USA, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B and ITGB3

      Variant: ITGA2B: NM_000419.3:c.2264G>A (p.Arg755Gln) NM_000212.2:c.392G>C (p.Arg131Pro) and NM_000212.2:c.777+1G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602771, CA8622954, CA8623036

      gnomAD: MAF in the Latino population is 0.0001903 https://gnomad.broadinstitute.org/variant/17-42454380-C-T and MAF in the African population is 0.00006152 https://gnomad.broadinstitute.org/variant/17-45361839-G-C and MAF in the African population is 0.0006774 https://gnomad.broadinstitute.org/variant/17-45363789-G-A

    4. Supplementary Table S1:

      Case8: GT9, French, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.665T>C (p.Leu222Pro) and NM_000212.2:c.1871G>A (p.Cys624Tyr)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224887 and CA400032726

      gnomAD: MAF in the European (non-Finnish) population is 0.00006482 https://gnomad.broadinstitute.org/variant/17-45363676-T-C

    5. Supplementary Table S1:

      Case18: GT21, French, gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.1440-13_1440-1del (p.Arg480Serfs106) and NM_000419.3:c.2864T>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913184940 and CA399791171

      gnomAD: N/A

    6. Supplementary Table S1:

      Case29: GT34, USA, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.1553T>A (p.Ile518Asn) and NM_000419.3:c.1946+3G>T

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8603038 and CA626121071

      gnomAD: MAF in the European (non-Finnish) population is 0.000008790 https://gnomad.broadinstitute.org/variant/17-42457661-A-T and MAF in the African population for NM_000419.3:c.1946+3G>T is 0.000 https://gnomad.broadinstitute.org/variant/17-42456008-C-A

    7. Supplementary Table S1:

      Case51: GT60, French/Italian, gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.1801T>C (p.Cys601Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623361

      gnomAD: MAF in the European (non-Finnish) population is 0.00001758 https://gnomad.broadinstitute.org/variant/17-45376784-T-C

    8. Supplementary Table S1:

      Case53: GT62, French, gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.31T>C (p.Trp11Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291240306

      gnomAD: N/A

    1. Case21: Patient GI, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGB3

      Variant: c.728T>T (Unregistered) GT database has the same variant listed and it won't show up in CAR

      LegacyVariant: ^

      ClinVar: ^

      CAiD: ^

      gnomAD: ^

    2. Case14: Patient LRI, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2113T>C (p.Cys705Arg)

      LegacyVariant: (p.Arg674Arg)

      ClinVar: N/A

      CAiD: CA8602816

      gnomAD: MAF in the European (non-Finnish) population is 0.000008792 https://gnomad.broadinstitute.org/variant/17-42455140-A-G

    3. Case2: Patient PF, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.416C>T (p.Ala139Val)

      LegacyVariant: (p.Ala108Val)

      ClinVar: N/A

      CAiD: CA399806036

      gnomAD: N/A

    4. Case13: Patient BM, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2113T>C (p.Cys705Arg)

      LegacyVariant: (p.Arg674Arg)

      ClinVar: N/A

      CAiD: CA8602816

      gnomAD: MAF in the European (non-Finnish) population is 0.000008792 https://gnomad.broadinstitute.org/variant/17-42455140-A-G

    5. Case19: Patient SM, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGB3

      Variant: NM_000212.2:c.355C>T and NM_000212.2:c.1801T>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8622924 and CA8623361

      gnomAD: MAF in the South Asian population is 0.0001307 https://gnomad.broadinstitute.org/variant/17-45360909-C-T and MAF in the European non Finnish pop is 0.00001758 https://gnomad.broadinstitute.org/variant/17-45376784-T-C

    1. GT-29

      Case24: (GT-29) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT30 is related to GT29

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Moderate (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1651C>T (p.Arg551Trp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802348

      gnomAD: MAF in the East Asian population is 0.00005045 http://gnomad.broadinstitute.org/variant/17-42457471-G-A

    2. GT-43

      Case33: (GT-43) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT43-GT44 are related

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Severe (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1620G>C (p.Gln540His) and NM_000419.3:c.1616T>G (p.Leu539Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802407 and CA399802416

      gnomAD: N/A

    3. GT-12

      Case10: (GT-12) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Probands GT11 -GT14 are related to GT-12 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: not available (See Supplemental Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.727G>C (p.Asp243His)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400023600

      gnomAD: N/A

    4. GT-62

      Case50: (GT-62) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Severe (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B and ITGB3

      Variant: NM_000419.3:c.985G>T (p.Val329Phe) and NM_000212.2:c.1265G>A (p.Ser422Asn)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399804719 (p.Val329Phe) and CA291225740 (p.Ser422Asn)

      gnomAD: N/A

    1. Mila-1

      Case8: Patient Mila-1 (found in the GT database) gender and age are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978 (Bruising)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: 25% GPIIIa and GPIIb surface expression

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1073G>A (p.Arg358His)

      LegacyVariant: N/A

      ClinVar: 2896

      CAiD: CA115839

      gnomAD: N/A

      PreviouslyPublished: Reference number 19 in this article

    1. The proband was a 27-year old Danish woman

      Case1: Female, 27 years old, Danish

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Information on father, mother, brother and sister. (See Figure 1 for pedigree)

      ParentalGenotype: Pedigree from Figure 1 shows Father to have (p.Asn331Ser) and mother has (p.Arg786Trp) variant.

      CasePresentingHPOs: HP:0000978, HP:0001934, HP:0006298

      (Bruising, prolonged bleeding after minor trauma, prolonged bleeding after dental extraction)

      CaseHPOFreeText: Lifelong bleeding history

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: αIIbβ3 expression and activation and αvβ3 expression were assessed by flow cytometry (See Figure 1 and 2 for results)

      PlateletAggregation: Platelet aggregation was impaired in response to all stimuli except ristocetin, with low-normal response to collagen

      CasePreviousTesting: To identify DNA variants, all exons of ITGA2B and ITGB3 were analyzed by Sanger sequencing

      Gene: ITGB3

      Variant: NM_000212.2:c.2356C>T (p.Arg786Trp) an NM_000212.2:c.992A>G (p.Asn331Ser)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400034866 (p.Arg786Trp) and CA400025729 (p.Asn331Ser)

      gnomAD: MAF for (p.Arg786Trp) in the African population is 0.000 https://gnomad.broadinstitute.org/variant/17-45387559-C-T

    1. The patient is a 2-year-old female from China

      Case1: Female, 3 years old, Chinese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A (No information about the family was available since the child was adopted)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421 (Epistaxis)

      CaseHPOFreeText: Mucocutaneous hemorrhages, prolonged bleeding time

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Protein expression was estimated by flow cytometry and western blot analysis. The analysis revealed less than 10% of surface expression of alphaIIbbeta3 relative to control platelets. (See Fig 2)

      PlateletAggregation: Platelet aggregation in response to ADP, collagen, adrenaline, and arachidonic acid was less than 5% that of control platelets, and no clot retraction was observed. Ristocetin-induced platelet agglutination and plasma fibrinogen content were within the normal range.

      CasePreviousTesting: Sequencing for mutations was carried out by direct sequencing of PCR overlapping fragments of reversed transcribed αIIb and β3 mRNA.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2829C>T (p.Pro943Leu), NM_000419.3:c.2621T>G (p.Ile874Ser), NM_000419.3:c.1750C>T (p.Arg584Ter)

      LegacyVariant: (p.Ile843Ser) and (p.Arg553Ter) and (p.Pro912Leu)

      ClinVar: 2891, 2892

      CAiD: CA500263536, CA115831, CA115834

      gnomAD: MAF in the European (Finnish) population is 0.4395 https://gnomad.broadinstitute.org/variant/17-42453065-A-C and MAF in the East Asian population is 0.0002176 https://gnomad.broadinstitute.org/variant/17-42457372-G-A

    1. 16CabGT-16

      Case16: (Proband CabGT-16), Male, age not specified, North African

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometry showed 2% GPIIb and 10% GPIIIa surface expression

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.2870C>T (p.Ser957Leu)

      LegacyVariant: N/A

      ClinVar: 2902

      CAiD: CA115850

      gnomAD N/A

    2. 22CabGT-22

      Case22: (Proband CabGT-22), Female, age not specified, South American

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression:

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGB3

      Variant: NM_000212.2:c.431T>G (p.Met144Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224645

      gnomAD N/A

    3. 10

      Case10: (Proband CabGT-10) Female, age not specifie,d North African

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Flow cytometry showed <5% GPIIIa and GPIIb surface expression

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.1878G>C (p.Gln626His)

      LegacyVariant: N/A

      ClinVar: 2903

      CAiD: CA115852

      gnomAD N/A

    1. 4

      Case4: Female, 35 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A per Table 1

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Prolonged ivy bleeding times, bleeding diathesis since early childhood

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Surface expression of αIIbβ3 was analyzed by flow cytometry which was 10-20% of normal

      PlateletAggregation: Aggregation in response to ADP, epinephrine and collagen was absent but normal in response to ristocetin

      CasePreviousTesting: Nucleotide sequences of the αIIb and β3 coding regions were determined by direct sequencing of RT-PCR products from platelet RNA.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2333A>C (p.Gln778Pro)

      LegacyVariant: (p.Gln747Pro)

      ClinVar: 225393

      CAiD: CA290947544

      gnomAD: MAF in the East Asian population is 0.0001087 https://gnomad.broadinstitute.org/variant/17-42453691-T-G

    2. cases 3

      Case3: Female, 32 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A per Table 1

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Prolonged ivy bleeding times, bleeding diathesis since early childhood

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Surface expression of αIIbβ3 was analyzed by flow cytometry which was 10-20% of normal

      PlateletAggregation: Aggregation in response to ADP, epinephrine and collagen was absent but normal in response to ristocetin

      CasePreviousTesting: Nucleotide sequences of the αIIb and β3 coding regions were determined by direct sequencing of RT-PCR products from platelet RNA.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2333A>C (p.Gln778Pro)

      LegacyVariant: (p.Gln747Pro)

      ClinVar: 225393

      CAiD: CA290947544

      gnomAD: MAF in the East Asian population is 0.0001087 https://gnomad.broadinstitute.org/variant/17-42453691-T-G

    1. A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia.

      Case1: Female, 20 years old, Chinese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Parents were heterozygous for mutation (See Fig 3)

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0000967, HP:0000979, HP:0000132

      (Epistaxis, gingival bleeding, petechiae, purpura, severe menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Surface GPIIb/IIIa expression was < 15% of normal

      Platelet Aggregation: Absent platelet aggregation in response to ADP, epinephrine, or collagen but normal response to ristocetin

      CasePreviousTesting: Direct sequencing of PCR amplified cDNA and GPIIIa exon VIII indicated that the patient was homozygous for the mutation

      Gene: ITGB3

      Variant: NM_000212.2:c.1199G>A (p.Cys400Tyr)

      LegacyVariant: (p.Cys374Tyr)

      ClinVar: 13562

      CAiD: CA123244

      gnomAD N/A

    1. GT 42

      Case30: GT42, Female, India, age of onset is 26 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.356G>A (p.Arg119Gln)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8622925

      gnomAD: MAF in the African population is 0.0002470 https://gnomad.broadinstitute.org/variant/17-45360910-G-A

    2. GT 60-1

      Case35: GT60-1, Female, India, age of onset is 27 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.428T>G (p.Leu143Trp)

      LegacyVariant: N/A

      ClinVar: 13567

      CAiD: CA123252

      gnomAD: MAF in the Other population is 0.0001629 https://gnomad.broadinstitute.org/variant/17-45361875-T-G

    3. GT 11

      Case19: GT11, Female, India, age of onset is 12 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.115T>G (p.Cys39Gly)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400031666

      gnomAD: N/A

    1. M/22

      Case4: Male, 22 years old, Tamil Nadu India

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0006298, HP:0000421, HP:0002239, HP:0000225

      (Prolonged bleeding after tooth extraction, epistaxis, GI bleeding, gingival bleeding)

      CaseHPOFreeText: Bleeding during tooth extraction

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1 for values

      PlateletAggregation: See Table 1 for values

      CasePreviousTesting: PCR amplification of ITAG2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1162G>A (p.Gly388Ser)

      LegacyVariant: (p.Gly357Ser)

      ClinVar: N/A

      CAiD: CA8603212

      gnomAD: N/A

    2. M/20

      Case9: Male, 20 years old, Tamil Nadu India

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0031364, HP:0000225, HP:0006298

      (Epistaxis, ecchymosis, gingival bleeding, prolonged bleeding after dental extraction)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1 for values

      PlateletAggregation: See Table 1 for values

      CasePreviousTesting: PCR amplification of ITAG2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.2489T>G (p.Leu830Arg)

      LegacyVariant: (p.Leu799Arg)

      ClinVar: N/A

      CAiD: CA8602667

      gnomAD: MAF in the South Asian population is 0.00003270 https://gnomad.broadinstitute.org/variant/17-42453313-A-C

    3. M/11

      Case7: Male, 1 years old, West Bengal India

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000225, HP:0006298, HP:0000967

      (Gingival bleeding, prolonged bleeding after tooth extraction, petechiae)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1 for values

      PlateletAggregation: See Table 1 for values

      CasePreviousTesting: PCR amplification of ITAG2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1651C>T (p.Arg551Trp)

      LegacyVariant: (p.Arg520Trp)

      ClinVar: N/A

      CAiD: CA399802348

      gnomAD: MAF in the East Asian population is 0.00005045https://gnomad.broadinstitute.org/variant/17-42457471-G-A

    1. Supplementary Tables 1 and 2 combined information:

      Case35: GT35, Male, 1 year old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364

      (Bruising, purpura, ecchymosis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed 10-20% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.625-1G>A (c.625-1G>A) and NM_000419.3:c.659A>G (p.Tyr220Cys)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805552 (c.625-1G>A) and CA399805484 (p.Tyr220Cys)

      gnomAD: MAF for (p.Tyr220Cys) in the South Asian population 0.00003266 https://gnomad.broadinstitute.org/variant/17-42462543-T-C

    2. Supplementary Tables 1 and 2 combined information:

      Case26: GT26, Male, 13 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364

      (Bruising, purpura, ecchymosis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2333A>C (Gln778Pro) and NM_000419.3:c.2671C>T (p.Gln891Ter)

      LegacyVariant: N/A

      ClinVar: 225393 (p.Gln778Pro)

      CAiD: CA290947544 (p.Gln778Pro) and CA8602626 (p.Gln891Ter)

      gnomAD: MAF in East Asian population: 0.0001087 https://gnomad.broadinstitute.org/variant/17-42453691-T-G

    3. Supplementary Tables 1 and 2 combined information:

      Case12: GT12, Male, 10 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Family history available per Table 1; however, no further information given

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421

      (Bruising, purpura, ecchymosis, epistaxis)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed 10-20% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2333A>C (p.Gln778Pro)

      LegacyVariant: N/A

      ClinVar: 225393

      CAiD: CA290947544

      gnomAD: N/A

    1. one of the patient affected

      Case1: Gender, age, and ethnicity not reported here

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.800G>A (p.Gln267Glu)

      LegacyVariant: (p.Gln236Glu)

      ClinVar: N/A

      CAiD: CA399805147

      gnomAD: N/A

      PreviouslyPublished: PMID: 12083483 (Access not available to this article)

    1. A 66-year-old male

      Case1: Male, 66 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Information of proband's child in Figure 2

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0011890

      (Prolonged bleeding following procedure)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: On admission to the hospital, proband had no sign or symptoms of bleeding.

      ProteinExpression: In comparison to normal platelets, very low αIIbβ3 (1,053 ± 544 copies/platelet, n=3) and αvβ3 (755 ± 180 copies/platelet, n=3) expression were measured on the cell surface expression of our patient’s platelets.

      PlateletAggregation: Light transmission aggregometry showed his platelets were unable to respond to ADP, collagen, arachidonic acid, and epinephrine; however, platelet agglutination in response to ristocetin was normal.

      CasePreviousTesting: To identify the molecular genetic defect in this patient, we isolated genomic DNA from the patient’s leukocytes and amplified all exons of ITGA2B and ITGB3 gene by PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.1697G>A (p.Gly566Asp)

      LegacyVariant: (p.Gly540Asp)

      ClinVar: N/A

      CAiD: CA400032338

      gnomAD: N/A

    1. The patient

      Case1: Male, elderly (specific age not specified), from Argentina (specific ethnicity not specified)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mild bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed patient's platelet aIIbb3 content was 40–50% of the usual range

      PlateletAggregation: Platelets failed to aggregate with all physiological agonists including thrombin

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.2332T>C (p.Ser778Pro)

      LegacyVariant: (p.Ser752Pro)

      ClinVar: 13556

      CAiD: CA123230

      gnomAD: N/A

      PreviouslyPublished: Caen, 1985; Chenet al, 1992 (PMID's not available at this time, go to these articles from this curated paper)

    1. male patient

      Case1: Male, French, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Son was heterozygous carriers of the p.Leu196Pro mutation (Sister died from nasal bleeding when she was a child)

      ParentalGenotype: Mother is heterozygous for p.Leu196Pro mutation (Father not alive)

      CasePresentingHPOs: HP:0000421 (Epistaxis)

      CaseHPOFreeText: Lifelong history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Expression showed 8% of normal platelet content for αIIbβ3

      PlateletAggregation: Absent aggregation to physiologic agonists

      CasePreviousTesting: Screened exons and splice sites of ITGB3 and ITGA2B genes of patient by single-strand conformation polymorphism analysis of PCR products.

      Gene: ITGB3

      Variant: NM_000212.2:c.665T>C (Leu222Pro) and NM_000212.2:c.1871G>A (p.Cys624Tyr)

      LegacyVariant: p.Leu196Pro and p.Cys598Tyr

      ClinVar: N/A

      CAiD: CA291224887 and CA400032726

      gnomAD: N/A

    1. The propositus is a 49 year-old French woman

      Case1: Female, 49 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia (diagnosed when 5 years old)

      FamilyInfo: A brother died from hemorrhage when he was 4 years old, but an adult sister has never experienced untoward bleeding. (Case History Supp Table 1)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0004406, HP:0000132, HP:0000225, HP:0000790

      (Easy bruising, recurrent epistaxis, menorrhagia, gingival bleeding, hematuria

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis showed no biding of P2 and AP-2, two MoAbs recognizing alphaIIbBeta3 and a very weak binding of MoAbs to Beta3 to platelets of the proband

      PlateletAggregation: Platelet function testing confirmed an absence of aggregation to ADP, collagen, arachidonic acid and thrombin but the response to ristocetin was normal (Case History Supp Table 1)

      CasePreviousTesting: Direct sequencing of all exons and splice sites of ITGA2B (30 exons) and ITGB3 (15 exons) was performed by the French National Sequencing Center. Briefly, exons and flanking regions of ITGA2B and ITGB3 were amplified by PCR with a high fidelity Taq polymerase permitting large fragment amplification. PCR fragments were sequenced.

      Gene: ITGB3

      Variant: (p.Pro189Ser)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA291224669

      gnomAD: MAF in European (non-Finnish) population is 0.00002638 http://gnomad.broadinstitute.org/variant/17-45362012-C-T

    1. GT10

      Case20: (GT10)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.59T>C (p.Leu20Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400028389

      gnomAD N/A

    2. GT72

      Case17: (GT72) Gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGB3

      Variant: NM_000212.2:c.1641C>G (p.Cys547Trp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400030171

      gnomAD N/A

    3. 58

      Case9: (GT58), Gender, age and ethnicity not reported

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1028T>C (p.Leu343Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399804619 (p.Leu343Pro)

      gnomAD N/A

    4. 69

      Case4: (GT69), Gender, age and ethnicity not reported

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NC_000017.11:g.44393555C>T (g.951G>A promoter variant) and NM_000419.3:c.1028T>C (p.Leu343Pro)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913189168 (promoter variant) and CA399804619 (p.Leu343Pro)

      gnomAD N/A

    1. GE

      Case8: Patient GE, gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGA2B

      Variant: NM_000419.3:c.2051T>G (p.Leu684Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399799849

      gnomAD: N/A

    1. Table 3 Molecular Diagnosis of Patients with Glanzmann Thrombasthenia:

      Case2: GT-2, age, gender, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: Segregation analysis confirmed in presence of heterozygous mutations in this proband.

      ParentalGenotype: Although segregation analysis confirmed, we do not know which variant in particular came from mom or dad.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients presented with a variable bleeding diathesis; most patients had epistaxis (54%), cutaneous bleeding (58%), and menorrhagia (100% of women) while other common symptoms (oral cavity, GI, following dental extraction of mild injuries, postpartum, or hematomas) were in general milder. There is no specific phenotypes attached to probands in this paper.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed that αIIbβ3 expression was less than 5%

      PlateletAggregation: There was severely impaired aggregation in response to all physiological agonists, and ristocetin induced platelet agglutination was normal or reduced to some extent.

      CasePreviousTesting: Total RNA from peripheral blood was used for cDNA synthesis for RT-PCR. Then, using specific oligonucleotides and conditions, they amplified and sequenced ITGA2B and ITGB3 by Sanger sequencing. Every mutation found in cDNA was confirmed in DNA samples.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2473_2481delinsTCACCTGGTC and NM_000419.3:c.641T>C (p.Leu214Pro)

      LegacyVariant: p.Leu183Pro

      ClinVar: (p.Leu214Pro is 2901)

      CAiD: CA915940289 and CA115848

      gnomAD: N/A

    1. Patient Osaka-5

      Case1: (Osaka-5) Female, 33 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed that the amount of αIIbβ3 expressed was about 6% of normal platelets

      PlateletAggregation: N/A

      CasePreviousTesting: Coding regions of ITGA2B and ITGB3 cDNAs were amplified by RT PCR

      Gene: ITGB3

      Variant: NM_000212.2:c.917A>C (p.His306Pro)

      LegacyVariant: (p.His280Pro)

      ClinVar: N/A

      CAiD: CA291224999

      gnomAD: https://gnomad.broadinstitute.org/variant/17-45364575-A-C

    1. J

      Case10: Patient ID J, Female, 5 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Related to Patient's I and K (See Table 1)

      ParentalGenotype: N/A (Parents are consangenous)

      CasePresentingHPOs: HP:0000978, HP:0004406, HP:0000225, HP:0002239

      (Easy bruising, recurrent epistaxis, gingival bleeding, GI bleeding

      CaseHPOFreeText: Hemorrhage after trauma, hematoma

      CaseNotHPOs: HP:0000967, HP:0000979, HP:0002239, HP:0000790, HP:0005261, HP:0002248

      (Petechiae, purpura, intracranial hemorrhage, hematuria, hemarthrosis, hematemesis)

      CaseNotHPOsFreeText: Hemorrhage after dental, ear bleeding

      ProteinExpression: N/A

      PlateletAggregation: Defective response to ADP, adrenaline, collagen, arachidonic acid, and normal response to ristocetin

      CasePreviousTesting: Exon PCR was used to amplify coding regions of the ITGA2B and ITGB3 genes. PCR products were purified and Sanger sequenced. Segregation using parental samples was undertaken when available.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1652G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602986

      gnomAD: MAF in South Asian population is 0.00006536 http://gnomad.broadinstitute.org/variant/17-42457470-C-T

      PreviouslyPublished: PMID: 19172520

    1. The proband

      Case#: Female, 29 yo

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Figure 2 Father and brother, unaffected carriers. Mother, unaffected negative. Sister, affected: Epistaxis, Cutaneous bleeding, Menorrhagia, Hematuria, Postpartum bleeding, Other bleeding symptoms (Ruptured corpus luteum bleeding)

      ParentalGenotype: Father carrier, unaffected. Mother negative, unaffected.

      CasePresentingHPOs: HP:0000421, Epistaxis. HP:0000132, Menorrhagia. HP:0000790, Hematuria. HP:0003540, Impaired platelet aggregation. HP:0001892, Abnormal bleeding. HP:0003010, Prolonged bleeding time. HP:0034263, Abnormal vaginal bleeding.

      PlateletAggregation: Normal platelet morphology, count 159 (125-350), MPV 10.6 fL (6.5-12.0), and PDW 12% (19-17). Decreased platelet aggregation: ADP 29.7& (30-70), Collagen 14.5% (30-70), AA 14.5% (40-80). Normal response to ristocetin, 88.7% (40-80). Thromboelastography (TEG) examination: hypocoagulable.

      CaseHPOFreeText: Cutaneous bleeding, Postpartum bleeding, Blood accumulation in the uterine cavity, Bleeding in ovaries, Vaginal bleeding during pregnancy,

      CaseNotHPOs: HP:0011875, Abnormal platelet morphology. HP:0011873, Abnormal platelet count.

      ProteinExpression: Protein structure model: destroyed local beta folding structure and molecular changes to structure of GPII beta helical region reduces the expression of GP IIb/IIIa. Proband refused further testing (flow cytometry).

      Gene: ITGA2B

      Variant: c.2822G>A, p. (Trp941Ter)

      HGVS: NM_000419.5:c.2822G>A

      ClinVar: absent

      CAID: CA399791662

      gnomAD: 0.00 https://gnomad.broadinstitute.org/variant/chr17-44375017-C-T?dataset=gnomad_r4

  2. watermark.silverchair.com watermark.silverchair.com
    1. Patient MK

      Case1: (Patient MK), Female, Pakistani, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000967, HP:0000979

      (Petechiae, purpura)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Figure 1 shows protein expression by flow cytometry

      PlateletAggregation: Absence of platelet aggregation in response to ADP, epinephrine, and collagen but a normal response to ristocetin

      CasePreviousTesting: Genomic DNA containing all of the exons of the aIIb and b3 genes and 500 bp of DNA immediately upstream of each transcriptional start site was isolated from the patient and normal controls. Screening for mutations was performed by using single stranded conformation polymorphism analysis. PCR amplification was performed as well.

      Gene: ITGB3

      Variant: NM_000212.2:c.428T>G (p.Leu143Trp)

      LegacyVariant: (p.Leu117Trp)

      ClinVar: 13567

      CAiD: CA123252

      gnomAD: MAF in the Other population is 0.0001629 https://gnomad.broadinstitute.org/variant/17-45361875-T-G

    1. 2

      Case2: Gender or age not specified, Thai ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Parental information available in Table 2

      ParentalGenotype: Father: p.Val206Asp/WT and Mother: also p.Val206Asp/WT (See Table 2)

      Note: Yes to parental consanguinity

      CasePresentingHPOs: N/A

      CaseHPOFreeText: The article does not mention specific bleeding phenotypes for each of the 4 probands in the article, rather, there is a general statement that says: "The common presentations included recurrent epistaxis, bleeding in oral cavity, and easy-bruising spontaneously or after trauma"

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinEpression: General statement from the article that states that flow cytometry to assess the surface GPIIb/IIIa complex showed reduced expression for all probands.

      PlateletAggregation: The platelet aggregation test was typically defective with all physiological agonists except ristocetin, for all patients.

      CasePreviousTesting: Whole exome sequencing was performed on the 30 exons of ITGA2B and 15 exons in ITGB3. PCR and direct sequencing were then performed in the DNA samples of the patients and their available parents to verify the presence of the identified mutations.

      Gene: ITGA2B

      Variant: NM_000419.3:c.617T>A (p.Val206Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805578

      gnomAD: N/A

  3. www-thieme-connect-de.libproxy.lib.unc.edu www-thieme-connect-de.libproxy.lib.unc.edu
    1. 038–2012

      Case#: 038-2012

      DiseaseAssertion: Hemophilia A, mild

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: 5% < FVIII:C < 40%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: The 26 exons and their flanking regions of F8 were amplified by PCR using specific primers with a simple modification

      Gene: F8

      Variant: NM_000132.3:c.1834C>T

      LegacyVariant:

      ClinVar: No

      CAID: CA255129

      gnomAD:

    2. 047–1013

      Case#: 047-1013

      DiseaseAssertion: Hemophilia A, mild

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: 5% < FVIII:C < 40%, Inhibitor present

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: The 26 exons and their flanking regions of F8 were amplified by PCR using specific primers with a simple modification

      Gene: F8

      Variant: NM_000132.3:c.1492G>C

      LegacyVariant:

      ClinVar: No

      CAID: CA414912741

      gnomAD:

    3. 002–2010

      Case#: 002-2010

      DiseaseAssertion: Hemophilia A, severe

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C < 1%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: The 26 exons and their flanking regions of F8 were amplified by PCR using specific primers with a simple modification

      Gene: F8

      Variant: NM_000132.3:c.901C>T

      LegacyVariant:

      ClinVar: No

      CAID: CA414917990

      gnomAD:

    4. 035–2005

      Case#: 035-2005

      DiseaseAssertion: Hemophilia A, moderate

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: 1% < FVIII:C < 5%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: The 26 exons and their flanking regions of F8 were amplified by PCR using specific primers with a simple modification

      Gene: F8

      Variant: NM_000132.3:c.1175C>T

      LegacyVariant:

      ClinVar: No

      CAID: CA255095

      gnomAD:

    5. 068–2003

      Case#: 068-2003

      DiseaseAssertion: Hemophilia A, mild

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: 5% < FVIII:C < 40%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: The 26 exons and their flanking regions of F8 were amplified by PCR using specific primers with a simple modification

      Gene: F8

      Variant: NM_000132.3:c.5275G>A

      LegacyVariant:

      ClinVar: No

      CAID: CA414911087

      gnomAD:

    6. 004–2013

      Case#: 004-2013

      DiseaseAssertion: Hemophilia A, severe

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C < 1%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: The 26 exons and their flanking regions of F8 were amplified by PCR using specific primers with a simple modification

      Gene: F8

      Variant: NM_000132.3:c.6046C>T

      LegacyVariant:

      ClinVar: No

      CAID: CA255197

      gnomAD:

    7. 001–2052

      Case#: 001-2052

      DiseaseAssertion: Hemophilia A, mild

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: 5% < FVIII:C < 40%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: The 26 exons and their flanking regions of F8 were amplified by PCR using specific primers with a simple modification

      Gene: F8

      Variant: NM_000132.3:c.1988C>T

      LegacyVariant:

      ClinVar: No

      CAID: CA255135

      gnomAD:

    8. 050–1001

      Case#: 050-1001

      DiseaseAssertion: Hemophilia A, moderate

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C < 1%

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: The 26 exons and their flanking regions of F8 were amplified by PCR using specific primers with a simple modification

      Gene: F8

      Variant: NM_000132.3:c.6046C>T

      LegacyVariant:

      ClinVar: No

      CAID: CA255197

      gnomAD:

    9. 003–1002

      Case#: 003-1002

      DiseaseAssertion: Hemophilia A, severe

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C < 1%, Inhibitor present

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: The 26 exons and their flanking regions of F8 were amplified by PCR using specific primers with a simple modification

      Gene: F8

      Variant: NM_000132.3:c.493C>T

      LegacyVariant:

      ClinVar: No

      CAID: CA255065

      gnomAD:

    1. B83

      Case#: B83

      DiseaseAssertion: Hemophilia A, mild

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C Chr = 17, FVIII:AG = 19, inverse assay discrepancy present (OSA<CSA)

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: Coding region and intron/exon bound-aries of the F8 gene were amplified from all patient samples and directly sequenced using primers

      Gene: F8

      Variant: NM_000132.4:c.6448G>A

      LegacyVariant:

      ClinVar: No

      CAID: CA414907951

      gnomAD:

    2. A14 A15

      Case#: A14, A15

      DiseaseAssertion: Hemophilia A, mild

      FamilyInfo: NA

      ParentalTesting: NA

      CasePresentingHPOs: HP:0003125

      CaseHPOFreeText: FVIII:C = 15, FVIII:AG = 41, assay discrepancy present (OSA>CSA)

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: Coding region and intron/exon bound-aries of the F8 gene were amplified from all patient samples and directly sequenced using primers

      Gene: F8

      Variant: NM_000132.4:c.5530C>T

      LegacyVariant:

      ClinVar: No

      CAID: CA255170

      gnomAD:

    1. mutation

      Case#: HB348 (assumed male, Caucasian, 28 y/o)

      DiseaseAssertion: No disease assertion made

      FamilyInfo: Of the 30 families, germline or so- matic origins were found in 9 mothers, 5 maternal grandmothers, and 16 maternal grandfathers. For the 29 incomplete families, origins were found in 14 mothers, 5 maternal grandmothers, and 10 maternal grandfathers. Comparing the two family types shows no significant difference (P=0.29), suggesting that no major bias occurs in the analyses because of the inclusion of incomplete families

      ParentalTesting: N/A

      CasePresentingHPOs: N/A

      CaseNotHPOs: N/A

      CasePreviousTesting: N/A

      Gene: F9

      Variant: NM_000133.4:c.127C>T (p.Arg43Trp)

      ClinVar: 811505

      CAID: CA414435537

      gnomAD: Absent/Not Reported

    1. Arg- > Gln

      Case#: Patient C (assumed male)

      DiseaseAssertion: Severe, Sporadic Hemophilia B

      FamilyInfo: Patient C's mother and two sisters were also heterozygous; and the third sister was homozygous for cleavage and is a non-carrier

      ParentalTesting: Mother was heterozygous for the variant

      CasePresentingHPOs: HP:0011858

      CasePresentingHPOsFreeText: reduced factor IX activity (FIX:C: <1; FIX:Ag:65)

      CaseNotHPOs: N/A

      CasePreviousTesting: N/A

      Gene: F9

      Variant: NM_000133.4:c.128G>A (p.Arg43Gln)

      LegacyVariant: c.6365 G>A (p.Arg-4Gln)

      ClinVar: 810864

      CAID: CA414435539

      gnomAD: Absent/Not Reported